0001683168-21-005683.txt : 20211115 0001683168-21-005683.hdr.sgml : 20211115 20211115154538 ACCESSION NUMBER: 0001683168-21-005683 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Coeptis Therapeutics Inc. CENTRAL INDEX KEY: 0001819663 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 843998117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56194 FILM NUMBER: 211409824 BUSINESS ADDRESS: STREET 1: 105 BRADFORD RD, SUITE 420 CITY: WEXFORD STATE: PA ZIP: 15090 BUSINESS PHONE: 724-934-6467 MAIL ADDRESS: STREET 1: 105 BRADFORD RD, SUITE 420 CITY: WEXFORD STATE: PA ZIP: 15090 FORMER COMPANY: FORMER CONFORMED NAME: VININGS HOLDINGS, INC. DATE OF NAME CHANGE: 20200730 10-Q 1 coeptis_i10q-093021.htm FORM 10-Q
0001819663 false Q3 2021 12/31 0001819663 2021-01-01 2021-09-30 0001819663 2021-11-15 0001819663 2021-09-30 0001819663 2020-12-31 0001819663 2021-07-01 2021-09-30 0001819663 2020-07-01 2020-09-30 0001819663 2020-01-01 2020-09-30 0001819663 coep:ConsultingServicesMember 2021-07-01 2021-09-30 0001819663 coep:ConsultingServicesMember 2020-07-01 2020-09-30 0001819663 coep:ConsultingServicesMember 2021-01-01 2021-09-30 0001819663 coep:ConsultingServicesMember 2020-01-01 2020-09-30 0001819663 coep:OtherSalesMember 2021-07-01 2021-09-30 0001819663 coep:OtherSalesMember 2020-07-01 2020-09-30 0001819663 coep:OtherSalesMember 2021-01-01 2021-09-30 0001819663 coep:OtherSalesMember 2020-01-01 2020-09-30 0001819663 coep:PreferredStockSeriesBMember 2019-12-31 0001819663 us-gaap:CommonStockMember 2019-12-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001819663 coep:CommonStockSubscribedMember 2019-12-31 0001819663 us-gaap:RetainedEarningsMember 2019-12-31 0001819663 2019-12-31 0001819663 coep:PreferredStockSeriesBMember 2020-01-01 2020-03-31 0001819663 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001819663 coep:CommonStockSubscribedMember 2020-01-01 2020-03-31 0001819663 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001819663 2020-01-01 2020-03-31 0001819663 coep:PreferredStockSeriesBMember 2020-03-31 0001819663 us-gaap:CommonStockMember 2020-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001819663 coep:CommonStockSubscribedMember 2020-03-31 0001819663 us-gaap:RetainedEarningsMember 2020-03-31 0001819663 2020-03-31 0001819663 coep:PreferredStockSeriesBMember 2020-04-01 2020-06-30 0001819663 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001819663 coep:CommonStockSubscribedMember 2020-04-01 2020-06-30 0001819663 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001819663 2020-04-01 2020-06-30 0001819663 coep:PreferredStockSeriesBMember 2020-06-30 0001819663 us-gaap:CommonStockMember 2020-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001819663 coep:CommonStockSubscribedMember 2020-06-30 0001819663 us-gaap:RetainedEarningsMember 2020-06-30 0001819663 2020-06-30 0001819663 coep:PreferredStockSeriesBMember 2020-07-01 2020-09-30 0001819663 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001819663 coep:CommonStockSubscribedMember 2020-07-01 2020-09-30 0001819663 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001819663 coep:PreferredStockSeriesBMember 2020-09-30 0001819663 us-gaap:CommonStockMember 2020-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001819663 coep:CommonStockSubscribedMember 2020-09-30 0001819663 us-gaap:RetainedEarningsMember 2020-09-30 0001819663 2020-09-30 0001819663 coep:PreferredStockSeriesBMember 2020-12-31 0001819663 us-gaap:CommonStockMember 2020-12-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001819663 coep:CommonStockSubscribedMember 2020-12-31 0001819663 us-gaap:RetainedEarningsMember 2020-12-31 0001819663 coep:PreferredStockSeriesBMember 2021-01-01 2021-03-31 0001819663 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001819663 coep:CommonStockSubscribedMember 2021-01-01 2021-03-31 0001819663 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001819663 2021-01-01 2021-03-31 0001819663 coep:PreferredStockSeriesBMember 2021-03-31 0001819663 us-gaap:CommonStockMember 2021-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001819663 coep:CommonStockSubscribedMember 2021-03-31 0001819663 us-gaap:RetainedEarningsMember 2021-03-31 0001819663 2021-03-31 0001819663 coep:PreferredStockSeriesBMember 2021-04-01 2021-06-30 0001819663 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001819663 coep:CommonStockSubscribedMember 2021-04-01 2021-06-30 0001819663 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001819663 2021-04-01 2021-06-30 0001819663 coep:PreferredStockSeriesBMember 2021-06-30 0001819663 us-gaap:CommonStockMember 2021-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001819663 coep:CommonStockSubscribedMember 2021-06-30 0001819663 us-gaap:RetainedEarningsMember 2021-06-30 0001819663 2021-06-30 0001819663 coep:PreferredStockSeriesBMember 2021-07-01 2021-09-30 0001819663 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001819663 coep:CommonStockSubscribedMember 2021-07-01 2021-09-30 0001819663 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001819663 coep:PreferredStockSeriesBMember 2021-09-30 0001819663 us-gaap:CommonStockMember 2021-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001819663 coep:CommonStockSubscribedMember 2021-09-30 0001819663 us-gaap:RetainedEarningsMember 2021-09-30 0001819663 coep:ConsensiLicenseRightMember 2021-09-30 0001819663 coep:ConsensiLicenseRightMember 2020-12-31 0001819663 coep:VyGenOptionsMember 2021-01-01 2021-05-06 0001819663 coep:VyGenMember 2020-10-01 2021-08-15 0001819663 coep:NotePayableMember 2021-09-30 0001819663 coep:NotePayableMember 2021-01-01 2021-09-30 0001819663 coep:NotePayable1Member 2020-12-31 0001819663 coep:NotePayable2Member 2021-09-30 0001819663 coep:NotePayable2Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable2Member 2020-12-31 0001819663 coep:NotePayable3Member 2021-09-30 0001819663 coep:NotePayable3Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable3Member 2020-12-31 0001819663 coep:NotePayable4Member 2021-09-30 0001819663 coep:NotePayable4Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable4Member 2020-12-31 0001819663 coep:NotePayable5Member 2021-09-30 0001819663 coep:NotePayable5Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable5Member 2020-12-31 0001819663 coep:NotePayable6Member 2021-09-30 0001819663 coep:NotePayable6Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable6Member 2020-12-31 0001819663 coep:NotePayable7Member 2021-09-30 0001819663 coep:NotePayable7Member 2020-12-31 0001819663 coep:LicenseAgreementMember coep:PurpleBioTechMember 2021-09-30 0001819663 coep:LicenseAgreementMember coep:PurpleBioTechMember 2021-01-01 2021-09-30 0001819663 coep:PppLoanMember 2020-01-01 2020-05-06 0001819663 coep:PppLoanMember 2021-01-01 2021-02-28 0001819663 coep:PppLoanMember 2021-09-30 0001819663 coep:PppLoanMember 2020-12-31 0001819663 coep:EidlLoanMember 2020-01-01 2020-07-08 0001819663 coep:EidlLoanMember 2020-07-08 0001819663 coep:EidlLoanMember 2021-09-30 0001819663 coep:EidlLoanMember 2020-12-31 0001819663 us-gaap:CommonStockMember 2021-09-30 0001819663 us-gaap:CommonStockMember 2020-09-30 0001819663 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001819663 coep:SeriesBConvertiblePreferredStockMember 2021-09-30 0001819663 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001819663 coep:CoralInvestmentPartnersMember coep:WarrantClassAMember 2020-11-23 0001819663 coep:CoralInvestmentPartnersMember coep:WarrantClassBMember 2020-11-23 0001819663 coep:WarrantHolderMember coep:CommonStockWarrantsMember 2021-05-28 0001819663 coep:WarrantHolder1Member coep:CommonStockWarrantsMember 2021-05-28 0001819663 coep:WarrantHolder2Member coep:CommonStockWarrantsMember 2021-05-28 0001819663 coep:WarrantHolderMember coep:CommonStockWarrantsMember 2021-07-30 0001819663 coep:WarrantHolder1Member coep:CommonStockWarrantsMember 2021-07-30 0001819663 coep:WarrantHolder2Member coep:CommonStockWarrantsMember 2021-07-30 0001819663 coep:AssetPurchaseAgreementMember coep:AniPharmaceuticalsMember 2019-01-01 2019-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transaction period from _____________ to _____________

 

Commission File No. 000-56194

 

Coeptis Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 84-3998117
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

 

105 Bradford Rd, Suite 420

Wexford, Pennsylvania

15090
(Address of principal executive offices (Zip Code)

 

(724) 934-6467

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of exchange on which registered
N/A N/A N/A

 

Securities registered pursuant to Section 12(g) of the Act: : Common Stock, par value $0.0001 per share

 

Indicate by check mark whether the registrant: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐
Non-accelerated Filer Smaller Reporting Company
Emerging Growth Company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes ☐  No ☒

 

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

 

The number of shares outstanding of the registrant’s common stock, par value $0.0001 per share, as of November 15, 2021, was 36,441,999.

 

 

 

   

 

 

COEPTIS THERAPEUTICS, INC.

FORM 10-Q

For the Quarter Ended September 30, 2021

 

TABLE OF CONTENTS

 

 

PART I – FINANCIAL INFORMATION
Item 1. Condensed Consolidated Unaudited Financial Statements 3
  Balance Sheets 3
  Statements of Operations 4
  Statements of Stockholders' Equity (Deficit) 5
  Statements of Cash Flows 6
  Notes to Financial Statements 7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 13
Item 3. Quantitative and Qualitative Disclosures About Market Risk 17
Item 4. Controls and Procedures 17
     
PART II -- OTHER INFORMATION  
Item 1. Legal Proceedings 19
Item 1A. Risk Factors 19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 3. Defaults Upon Senior Securities 19
Item 4. Mine Safety Disclosures 19
Item 5. Other Information 19
Item 6. Exhibits 19

 

 

 

 

 2 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1.Unaudited Financial Statements

 

COPETIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

           
  September 30,
2021
   December 31,
2020
 
ASSETS
CURRENT ASSETS          
Cash  $2,809,861   $202,965 
Accounts receivable   26,302    21,786 
Inventories        
TOTAL CURRENT ASSETS   2,836,164    224,751 
           
PROPERTY AND EQUIPMENT          
Furniture and fixtures   25,237    25,237 
Less: accumulated depreciation   (10,944)   (9,730)
Furniture and fixtures, net   14,293    15,507 
OTHER ASSETS          
Co-development options   4,804,167     
Right-of-use asset, net of accumulated amortization   28,352    58,225 
Other assets       2,000 
Total other assets   4,832,519    60,225 
TOTAL ASSETS  $7,682,976   $300,484 
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) 
CURRENT LIABILITIES          
Accounts payable  $1,281,314   $1,623,840 
Accrued expenses   153,811    732,146 
Notes payable, current portion   3,999,595    1,277,500 
Notes payable, related parties, current portion       604,000 
Right of use liability, current portion   10,758    41,618 
Deferred revenue       1,000,000 
TOTAL CURRENT LIABILITIES   5,445,478    5,279,104 
           
LONG TERM LIABILITIES          
Note payable   1,650,000    150,000 
Right of use liability, non-current portion   14,723    14,723 
TOTAL LONG TERM LIABILITIES   1,664,723    164,723 
TOTAL LIABILITIES  $7,110,201   $5,443,827 
           
COMMITMENTS AND CONTINGENCIES (NOTE 7)          
           
STOCKHOLDERS' EQUITY (DEFICIT)          
Series B Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, 8,000 and -0- shares issued and outstanding, respectively     1        
Common stock, $0.0001 par value, 750,000,000 shares authorized, 34,750,733 and 25,178,840 shares issued and outstanding, respectively     3,317       2,519   
Additional paid-in capital   23,902,974    8,954,985 
Common stock subscribed   1,377,000     
Accumulated deficit   (24,710,518)   (14,100,846)
TOTAL STOCKHOLDERS' EQUITY   572,774    (5,143,342)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $7,682,976   $300,484 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 

 

 3 

 

COEPTIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

                     
   Three Months Ended   Nine Months Ended 
   September 30,
2021
   September 30,
2020
   September 30,
2021
   September 30,
2020
 
SALES                
Consulting services  $   $9,888   $75,000   $30,761 
Sales                
Total sales       9,888    75,000    30,761 
Cost of goods, including inventory obsolescence       1,492        3,361 
Gross profit       8,396    75,000    27,400 
                     
COST OF OPERATIONS                    
Research and development               3,543 
General and administrative expenses   6,759,339    1,433,621    11,077,747    2,437,725 
Selling and marketing           2,918     
Interest expense   188,559    183,871    266,382    262,826 
Total operating expenses   6,947,898    1,617,492    11,347,048    2,704,094 
                     
LOSS FROM OPERATIONS   (6,947,898)   (1,609,097)   (11,272,048)   (2,676,694)
                     
OTHER INCOME (EXPENSE)                    
                     
Royalties and licensing fees   3,543    (211,550)   (413,124   (1,711,550)
Licensing income   1,000,000        1,000,000     
Other Income           77,500     
Gain (Loss) on write down of assets   (2,000)       (2,000)    
TOTAL OTHER INCOME (EXPENSE)   1,001,543    (211,550)   662,376    (1,711,550)
                     
LOSS BEFORE INCOME TAXES   (5,946,356)   (1,820,647)   (10,609,672)   (4,388,244)
                     
PROVISION FOR INCOME TAXES (BENEFIT)                
NET LOSS  $(5,946,356)  $(1,820,647)  $(10,609,672)  $(4,388,244)
                     
LOSS PER SHARE                    
                     
Loss per share, basic and fully diluted  $(0.17)  $(0.09)  $(0.34)  $(0.23)
                    
Weighted average number of common shares outstanding   34,060,556    20,164,597    31,054,813    18,756,999 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 

 

 4 

 

 

 

COEPTIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

(Unaudited)

 

 

                                 
  SERIES B      ADDITIONAL  COMMON       
  PREFERRED STOCK  COMMON STOCK  PAID-IN  STOCK  ACCUMULATED    
SHARES  AMOUNT  SHARES  AMOUNT  CAPITAL  SUBSCRIBED  DEFICIT  TOTAL 
BALANCE AT DECEMBER 31, 2019    $   16,196,000  $1,620  $5,464,465  $100,000  $(4,944,559) $621,526 
Retroactive application of recapitalization     1,588,800      (297,949)        (297,949)   
Adjusted balance, beginning of period        17,784,800   1,620   5,166,516   100,000   (4,944,559)  323,577 
Shares issued for cash        200,000   20   99,980   (100,000)      
Net income (loss)                    (1,896,399)  (1,896,399)
BALANCE AT MARCH 31, 2020    $   17,984,800  $1,640  $5,266,496  $  $(6,840,958) $(1,572,822)
Shares issued for cash                        
Shares issued for services        667,840   67   333,853         333,920 
Net income loss)                    (685,254)  (685,254)
BALANCE AT JUNE 30, 2020    $   18,652,640  $1,707  $5,600,349  $  $(7,526,212) $(1,924,156)
Shares issued for cash        3,300,000   330   649,670   100,000      750,000 
Shares issued for services                        
Net income (loss)                    (1,820,647)  (1,820,647)
BALANCE AT SEPTEMBER 30, 2020    $   21,952,640  $2,037  $6,250,019  $100,000  $(9,346,859) $(2,994,803)
BALANCE AT DECEMBER 31, 2020    $   25,178,840  $2,519  $8,954,985    (14,100,846) $(5,143,342)
Retroactive application of recapitalization  8,000   1   1,589,400      (298,062)        (298,061)
Shares issued for cash        2,436,500   244   2,436,256   471,000      2,907,500 
Shares issued for services        770,000   77   769,923         770,000 
Net income (loss)                    (1,950,081)  (1,950,081)
BALANCE AT MARCH 31, 2021  8,000  $1   29,974,740  $2,839  $11,863,102  $471,000  $(16,050,927) $(3,713,985)
Shares issued for cash        1,281,664   128   1,922,368   (388,500)     1,533,996 
Shares issued for services        690,000   69   1,034,931         1,035,000 
Warrants issued for services              676,892         676,892 
Shares issued through conversion of debt        694,000   69   1,040,931         1,041,000 
Net income (loss)                    (2,713,235)  (2,713,235)
BALANCE AT JUNE 30, 2021  8,000  $1   32,640,404  $3,106  $16,538,223  $82,500  $(18,764,162) $(2,140,332)
Shares issued for cash        1,705,329   171   2,557,828   1,294,500      3,852,499 
Shares issued for services        405,000   41   607,460         607,500 
Warrants issued for services              2,301,879         2,301,879 
Stock based compensation              1,897,585         1,897,585 
Net income (loss)                    (5,946,356)  (5,946,356)
BALANCE AT SEPTEMBER 30, 2021  8,000  $1   34,750,733  $3,317  $23,902,975  $1,377,000  $(24,710,518) $572,774 


The accompanying notes are an integral part of the consolidated financial statements.

 

 

 5 

 

 

COEPTIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

           
  Nine Months Ended 
  September 30, 2021   September 30, 2020 
OPERATING ACTIVITIES          
Net income (loss)  $(10,609,672)  $(4,388,244)
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:          
Depreciation and amortization   1,214    1,444 
Forgiveness of debt   (77,500)    
Interest paid        
Shares issued for non-employee services   2,412,500    333,920 
Warrants issued for services   2,978,771     
Stock based compensation   1,897,585     
Shares issued for conversion of debt   1,041,000     
(Increase) decrease in:          
Accounts receivable   (4,516)   (14,907)
Inventories       (1,014,659)
Right of use asset/liability   (988)   1,945 
Increase (decrease) in:          
Accounts payable   (340,621)   1,916,183 
Accrued expenses   (578,335)   112,806 
Deferred revenue   (1,000,000)   500,000 
NET CASH USED IN OPERATING ACTIVITIES   (4,280,561)   (2,551,512)
           
INVESTING ACTIVITIES          
Purchase of license right   (4,804,167)    
Purchase of property and equipment        
NET CASH USED IN INVESTING ACTIVITIES   (4,804,167)    
           
FINANCING ACTIVITIES          
Proceeds from notes payable   4,827,595    1,227,500 
Proceeds from notes payable, related parties       604,000 
Repayment of notes payable   (527,905)    
Repayment of notes payable, related parties   (604,000)    
Shares from merger transaction   (298,061)    
Shares issued for cash   6,916,994    650,000 
Cash received for stock subscription   1,377,000    100,000 
NET CASH PROVIDED BY FINANCING ACTIVITIES   11,691,623    2,581,500 
NET INCREASE IN CASH   2,606,897    29,988 
CASH AT BEGINNING OF PERIOD   202,965    440,088 
CASH AT END OF PERIOD  $2,809,861   $470,076 
           
SUPPLEMENTAL DISCLOSURES          
Interest paid  $   $ 
Taxes paid (refunded)  $   $ 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 

 

 6 

 

COEPTIS THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(UNAUDITED)

 

 

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Nature of Business – Coeptis Pharmaceuticals, LLC (LLC) was formed in July 12, 2017 as a Pennsylvania multi-member limited liability company. On December 1, 2018, the members of LLC contributed their interest to a newly formed corporation, Coeptis Pharmaceuticals, Inc (“Coeptis”). As of December 1, 2018, the LLC became a disregarded single-member limited liability company which is wholly owned by the newly formed corporation. On February 12, 2021, Vinings Holdings, Inc., a Delaware corporation (“Vinings”), merged (the “Merger”) with and into Coeptis Pharmaceuticals, Inc. On July 12, 2021, the company has legally changed its name from Vinings Holdings, Inc. to Coeptis Therapeutics, Inc. Coeptis was the surviving corporation of that Merger. As a result of the Merger, Vinings acquired the business of Coeptis and will continue the existing business operations of Coeptis as a wholly owned subsidiary. The Merger was treated as a recapitalization of the Company for financial accounting purposes. The historical financial statements of Vinings before the Merger were replaced with the historical financial statements of Coeptis before the Merger in all future filings with the Securities and Exchange Commission (the “SEC”).

 

The Company is located in Wexford, PA, and engages primarily in the acquisition, development, and commercialization of pharmaceutical products.

 

Basis of Presentation - The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of September 30, 2021, along with its results of operations for the three and nine month periods ended September 30, 2021 and 2020 and cash flows for the nine-month periods ended September 30, 2021 and 2020. Interim financial statements are prepared on a basis consistent with the Company’s annual financial statements and should be read in conjunction with our Annual Report on Form 10-KT for the fiscal year ended December 31, 2020. Results of operations for the nine-month period ended September 30, 2021, are not necessarily indicative of the operating results that may be expected for the full year ending December 31, 2021.

 

As a result of the Merger, the financial statements included in this report reflect (1) the historical operating results of Coeptis prior to the Merger; (2) the combined results of the Company and Coeptis following the closing of the Merger; (3) the assets and liabilities of Coeptis at their historical cost; and (4) the Company’s equity structure for all periods presented.

 

Risks and Uncertainties - In late 2019, an outbreak of a novel strain of the Coronavirus 2019 Disease (COVID-19) was identified and infections have been found in a number of countries around the world, including the United States. COVID-19 and its impact on trade including customer demand, travel, employee productivity, supply chain, and other economic activities has had, and may continue to have, a potentially significant effect on financial markets and business activity. The extent of the impact of COVID-19 on the Company’s operational and financial performance is currently uncertain and cannot be predicted.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company’s significant accounting policies are described in Note 2 “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-KT filed with the U.S. Securities and Exchange Commission (“SEC”) on May 11, 2021. There have been no material changes to the significant accounting policies during the period ended September 30, 2021, except for items mentioned below.

 

Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Coeptis Therapeutics Inc., Coeptis Pharmaceuticals, Inc. and its wholly-owned subsidiary, Coeptis Pharmaceuticals, LLC. All material intercompany accounts, balances and transactions have been eliminated.

 

Use of Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 

 

 7 

 

 

Accounting for non-employee share-based paymentsThe Company may from time to time issue share based compensation to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to equity instruments for the settlement of services provided by non-employees is recorded on the statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. Warrants that provide the option to purchase common stock are accounted for in accordance with ASC 718-10-35-1D, where the total cost of the compensation is based on the number of instruments for which a service has been rendered, and recognized over the period that the service is performed. To determine the amount of compensation cost to be recognized in each period, the Company shall recognize the effect of forfeitures in compensation cost when they occur. Previously recognized compensation cost shall be reversed in the period that the award is forfeited.

 

Adoption of New Accounting Pronouncements – In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.

 

During the nine months ended September 30, 2021, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

 

NOTE 3 – LICENSE RIGHT

 

In 2019, the Company entered into an agreement with a foreign entity to market, distribute, and sell the Consensi product (Product) on an exclusive basis within the United States and Puerto Rico. Upon execution of the Agreement the Company paid $1,000,000 to the foreign entity. Milestone payments were due as follows; (1) $1,500,000 upon completion of the CMC Plan as reimbursements of costs incurred by the foreign entity, (2) $1,000,000 was due upon first commercial sale of the Product which occurred in June 2020. Milestones were not met during nine months ended September 30, 2021 and 2020.

 

During the fourth quarter of 2020, the Company determined that there was a reduction of the useful life of the asset, resulting in a full impairment of the asset. The carrying value of the license right at September 30, 2021 and December 31, 2020 was $0. Amortization expenses total $0 and $0 for the nine months ended September 30, 2021 and 2020, respectively.

 

In September of 2021, the Company executed a license termination agreement with the foreign entity to cease all efforts for sales and promotion of the product in the United States and Puerto Rico. The termination included issuance of $1,500,000 of convertible debt due in 2023 to satisfy amounts owed for the license, issue of warrants (See NOTE 5) and transfer of inventory ownership back to the foreign entity. In conjunction with this termination, the Company also terminated its marketing agreement with a third party for the Product’s sales and promotion.

 

On May 6, 2021, the Company made initial payments under two definitive agreements. The two definitive option purchase agreements are with VyGen-Bio, Inc. (“Vy-Gen”), pursuant to which the Company has the exclusive option to acquire co-development rights with respect to two Vy-Gen product candidates. The Company paid a total of $750,000 to acquire the two exclusive options. On August 15, 2021, the Company entered into amendments to each of the two definitive option purchase agreements, in connection with such amendments the Company delivered promissory notes aggregating $3,250,000 with maturity dates of December 31, 2021. In connection with the two amendments the Company plans to pay a cash payment of $1,000,000, and thereby the Company will be deemed to have exercised the two options. In the event that the promissory notes are timely paid by December 31, 2021, the Company will maintain its 50% ownership interest in the two Vy-Gen product candidates, and if the promissory notes are not timely paid by December 31, 2021 the Company’s ownership interest in such assets will automatically be reduced to 20%, in which case the two promissory notes will be automatically cancelled and will no longer be due or payable.

 

 

 

 8 

 

 

NOTE 4 – LONG-TERM DEBT

 

The Company entered into a note payable agreement with an unrelated company with a conversion option. The principal amount of $200,000, which is unsecured, together with interest at 9% was due June 15, 2020. In lieu of cash repayment, the outstanding principal amount of the note, plus all accrued unpaid interest may be converted at the option of the party, in whole or in part, into shares of Common Stock. As of the December 31, 2020, the note had a balance of $200,000. The note and accrued interest were paid in full in the first quarter of 2021.

 

In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $500,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. The balance of the note is $500,000 as of September 30, 2021 and December 31, 2020. This debt is currently in default.

 

In January 2020, the Company entered into a Senior Secured Note agreement with a related party stockholder. The principal amount of $250,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. This debt was converted to equity in June 2021. The balance of the note was $0 and $250,000 as of September 30, 2021 and December 31, 2020, respectively.

 

In January 2020, the Company entered into another Senior Secured Note agreement with a stockholder. The principal amount of $250,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. This debt was converted to equity in June 2021. The balance of the note is $0 and $250,000 as of September 30, 2021 and December 31, 2020, respectively.

 

In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $333,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. This debt was converted to equity in June 2021. The balance of the note was $0 and $333,000 as of September 30, 2021 and December 31, 2020, respectively.

 

In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $167,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. The balance of the note is $167,000 as of September 30, 2021 and December 31, 2020. This debt is currently in default.

 

In September 2020, the Company entered a non-interest bearing, unsecured note agreement with two shareholders for $104,000 with an unspecified due date. The note was converted to equity in June 2021. The balance was $0 and $104,000 as of September 30, 2021 and December 31, 2020.

 

In September 2021, as part of a termination of license agreement with Purple BioTech, the Company issued a convertible note in the principle amount of $1,500,000 that is payable on or before February 2023, bearing interest of 5% per annum and convertible in whole or in part at any time by Purple BioTech into shares of Coeptis’ common stock. The conversion price is $5 per share of common stock, subject to certain adjustments under such terms and conditions as agreed between the parties. Coeptis may prepay the principal amount of the Note plus accrued and unpaid interest at any time, prior to the Maturity Date. Inventory, which has been fully written-off on the Company’s balance sheet, will be transferred back to Purple at Purple’s cost.

 

Interest accrued on the related party notes at September 30, 2021 and December 31,2020 was $0 and $40,000, respectively.

 

Loans under the CARES Act -- On May 6, 2020, the Company received loan proceeds in the amount of approximately $77,500 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. In February 2021, an additional $77,595 was received by the Company under the second round of PPP (“PPP2”). The Company has used the proceeds for purposes consistent with its intended use. The initial loan was forgiven in the amount of $77,500 in principal and $893.40 in interest on June 25, 2021. The Company applied for PPP2 loan forgiveness in September 2021 and received full forgiveness in October 2021. As of September 30, 2021, and December 31, 2020, the balance of the notes totaled $77,595 and $77,500, respectively.

 

 

 

 9 

 

 

On July 8, 2020 the Company received a loan of $150,000 from the from the United States Small Business Administration (the “SBA”) under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Proceeds are intended to be used for working capital purposes. Interest on the EIDL Loan accrues at the rate of 3.75% per annum and installment payments, including principal and interest, are due monthly beginning July 2022 in the amount of $731. The balance of principal and interest is payable thirty years from the date of the promissory note. The balance of the loan is $150,000, as of September 30, 2021 and December 31, 2020.

 

Maturities of long-term debt for the quarter ended September 30, 2021 are as follows: 

      
2022    
2023   1,502,001 
2024   5,279 
2025   8,682 
Thereafter   134,038 
Total long-term debt  $1,650,000 

 

NOTE 5 – CAPITAL STRUCTURE

 

The total number of shares of stock which the corporation shall have authority to issue is 760,000,000 shares, of which 750,000,000 shares of $0.0001 par value shall be designated as Common Stock and 10,000,000 shares of $0.0001 shall be designated as Preferred Stock. The Preferred Stock authorized by these Articles of Incorporation may be issued in one or more series. The Board of Directors of the Corporation is authorized to determine or alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any series and to fix the numbers of shares of any series.

 

Common Stock - As of September 30, 2021 the Company had 34,750,733 shares of its common stock issued and outstanding, and on September 30, 2020 the Company had 21,952,640 shares of its common stock issued and outstanding. All references to the common shares outstanding have been retroactively adjusted to reflect the stock splits unless stated otherwise.

 

In 2021 and 2020, the Company raised capital by issuance of common stock above the stated par value. The contributed capital recognized as additional paid in capital during the nine months ended September 30, 2021 and 2020 was $13,064,256 and $5,952,069 respectively. During the nine months ended September 30, 2021 and 2020, there were $0 in capital distributions.

 

Series A Preferred Stock - As of April 30, 2019, the Series A Preferred Stock had been canceled, and no shares remain outstanding. The rights and privileges of future issuances of the Series A Preferred stock will be determined at such time if and when they are issued. As of September 30, 2021, there were 0 shares of Series A Preferred outstanding.

 

Series B Convertible Preferred Stock - The Company designated 2,000,000 shares of Series B Convertible Preferred Stock with a par value of $0.0001 per share. Initially, there will be no dividends due or payable on the Series B Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.

 

All shares of the Series B Preferred Stock shall rank (i) senior to the Corporation’s Common Stock and any other class or series of capital stock of the Corporation hereafter created, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series B Preferred Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series B Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.

 

 

 

 10 

 

 

The Series B Preferred shall have no liquidation preference over any other class of stock.

 

Each holder of outstanding shares of Series B Preferred Stock shall be entitled to the number of votes equal to equal to one thousand (1,000) Common Shares. Except as provided by law, or by the provisions establishing any other series of Preferred Stock, holders of Series B Preferred Stock and of any other outstanding series of Preferred Stock shall vote together with the holders of Common Stock as a single class.

 

Each holder of shares of Series B Preferred Stock may, at any time and from time to time, convert (an “Optional Conversion”) each of its shares of Series B Preferred Stock into a 1,000 of fully paid and nonassessable shares of Common Stock; provided, however, that any Optional Conversion must involve the issuance of at least 100 shares of Common Stock.

 

In the event of a reverse split, the conversion ratio shall not be changed. However, in the event a forward split shall occur then the conversion ratio shall be modified to be increased by the same ratio as the forward split.

 

The Company has evaluated the Series B Preferred Stock in accordance with ASC 815 and has determined their conversion options were for equity and ASC 815 did not apply as of September 30, 2021. The Company has evaluated the Series B Preferred Stock in accordance with FASB ASC Subtopic 47020 and has determined that there is no beneficial conversion feature that must be accounted for as of September 30, 2021.

 

As of September 30, 2021, there were 8,000 shares of Series B Preferred outstanding.

 

Common Stock Warrants - On November 23, 2020, the Company issued a class A and a class B warrant to Coral Investment Partners, LP (“CIP”), with each warrant granting CIP the right to purchase 500,000 shares of common stock at a price of $2 for Class A or $5 for Class B. The warrants expire on November 30, 2023. The warrants also contain a cashless exercise provision and contained anti-dilution provisions. The warrants remain outstanding as of September 30, 2021. Subsequent to the quarter end, the Company was notified by the warrant holder that they intend to exercise its right to purchase shares of the Company under these warrants. SEE NOTE 10.

 

On May 28, 2021, the Company issued a warrant to a third party in exchange for professional services, granting the warrant holder the right to purchase 500,000 shares of common stock at a price of $1 per share, 500,000 shares at $2 per share, and 500,000 at $5 per share. The warrants expire on June 1, 2026. All warrants were outstanding on September 30, 2021.

 

On July 30th, 2021, the Company issued a warrant to a third party in exchange for professional services, granting the warrant holder the right to purchase 200,000 shares of common stock at a price of $1 per share, 100,000 shares at $2 per share, and 100,000 at $5 per share. The warrants expire on July 26, 2026. All warrants were outstanding on September 30, 2021.

 

On September 22, 2021, the Company issued a warrant in conjunction with the termination of the license right (see Note 3) with Purple Biotech, granting Purple Biotech the right to purchase 300,000 shares of common stock at $5 per share, subject to certain adjustments. During the three and nine months ending September 30, 2021, the Company recorded $1,897,585 as general and administrative expense in condensed consolidated statement of operations upon immediate vesting of the Warrant. The warrant was valued using the Black-Scholes option pricing model using the following assumptions: 1) exercise price of $5.00 per share, 2) fair value of $6.50 per share, 3) discount rate of 0.48%, 3) dividend rate of 0%, and 4) a term of 3 years.

 

NOTE 6 – ASSET PURCHASE AGREEMENT

 

On June 18, 2019, the Company entered into an Asset Purchase Agreement with ANI Pharmaceuticals, Inc. (ANI) for the sale of certain intellectual property and materials related to the research and development related to potential ANDA candidates. The Company recognized revenue of approximately $2,300,000 related to the Asset Purchase Agreement in the year ended December 31, 2019.

 

In addition to the original purchase price, the Company is due an additional $2,000,000 with respect to the Product that is Vigabatrin 500mg tablets (tablets) as follows; (A) $250,000 within 30 days following the completion of all bioequivalence studies related to tablets, (B) $250,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $1,000,000 in a calendar year, (C) $500,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $5,000,000 in a calendar year, (D) $1,000,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $10,000,000 in a calendar year. As of nine months ended September 30, 2021 and 2020, and through this date, none of these milestones have occurred. Because collection of these milestone payments is not reasonably assured, we have not recorded any revenues in the accompanying financial statements.

 

 

 

 

 11 

 

 

Also, the Company is due an additional $1,750,000 with respect to the Product that is Vigabatrin 500mg powder for Oral Solution (powder) as follows; (A) $250,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $1,000,000 in a calendar year, (B) $500,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $5,000,000 in a calendar year, (C) $1,000,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $10,000,000 in a calendar year. As of nine months ended September 30, 2021 and 2020, and through this date, none of these milestones have occurred. Because collection of these milestone payments is not reasonably assured, we have not recorded any revenues in the accompanying financial statements.

 

NOTE 7 – COMMITMENTS AND CONTINGENCIES

 

Leases - The Company leases office space under an operating lease commencing December 1, 2017 through November 30, 2019 and a first lease extensions commending December 1, 2019 through May 31, 2020. The second lease extension extends the lease for twenty-four months, beginning on June 1, 2020 and ending on May 31, 2022. The monthly rent is $3,750. On January 1, 2019, the Company adopted ASC Topic 842, Leases, requiring this lease to be recorded as an asset and corresponding liability on its consolidated balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. During the nine months ended September 30, 2021 and 2020, rental expense totaled $33,750 and $32,250 respectively.

 

Future minimum rental payments required under the lease are as follows: 

     
2021 (remaining 3 months)  $11,250 
2022   18,750 

 

Legal Matters – The company is currently not a defendant in any litigation or threatened litigation that could have a material effect on the company’s financial statements.

 

Royalty Obligations - In connection with the product licensing agreement discussed in Note 3, the Company owes a minimum royalty payment of $1,000,000 following the first year of product sales. A minimum royalty amount is also due in subsequent years.

 

Royalty Advances - In the nine months ended September 30, 2021 and 2020, the Company received royalty advances on future product sales of $0 and $250,000, respectively, from its pharmaceutical marketing partner. Interest is due on this advance and will continue to accrue at the rate of 10% until the payment is fully recouped from royalties.

 

Minimum Payment Obligation – In connection with a supply agreement with Coeptis’ drug product distributor related to Consensi, an amendment was entered into which (i) removes the requirement of a minimum payment obligation from such product distributor to Coeptis in regard to the sale of Consensi and (ii) clarifies that the upfront payment that was made from the product distributor to Coeptis may only be recouped by the product distributor through an offset against royalty payments that may otherwise become payable to Coeptis under the supply agreement.

 

NOTE 8 - 401(k) PROFIT-SHARING PLAN

 

The Company sponsors a qualified profit-sharing plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee elective deferrals but has no contribution requirements for the Company. During the nine months ended September 30, 2021 and 2020, no employer contributions were made, and as of September 30, 2021 contributions to the plan will no longer be accepted as the plan is no longer active.

 

NOTE 9 – INCOME TAXES

 

For the nine months ended September 30, 2021 and 2020, respectively, no income tax expense or benefit was recognized. The Company’s deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception.

 

NOTE 10 – SUBSEQUENT EVENT

 

On October 1, 2021, the Company entered into an agreement with a Shareholder to surrender shares of Common Stock in exchange for the settlement of debt owed.

 

On October 20, 2021, the Company was notified by the Class A and Class B warrant holder that it is exercising its right to purchase shares of the company under its warrants.

 

 

 

 

 

 

 

 

 

 

 

 12 

 

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

This Report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 12E of the Securities Exchange Act of 1934, including or related to our future results, certain projections and business trends. Assumptions relating to forward-looking statements involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. When used in this Report, the words “estimate,” “project,” “intend,” “believe,” “expect” and similar expressions are intended to identify forward-looking statements. Although we believe that assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate, and we may not realize the results contemplated by the forward-looking statement. Management decisions are subjective in many respects and susceptible to interpretations and periodic revisions based on actual experience and business developments, the impact of which may cause us to alter our business strategy or capital expenditure plans that may, in turn, affect our results of operations. In light of the significant uncertainties inherent in the forward-looking information included in this Report, you should not regard the inclusion of such information as our representation that we will achieve any strategy, objective or other plans. The forward-looking statements contained in this Report speak only as of the date of this Report as stated on the front cover, and we have no obligation to update publicly or revise any of these forward-looking statements. These and other statements which are not historical facts are based largely on management’s current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by such forward-looking statements. These risks and uncertainties include, among others, the failure to successfully develop a profitable business, delays in identifying customers, and the inability to retain a significant number of customers, as well as the risks and uncertainties described in “Risk Factors” section to our Annual Report for the fiscal year ended December 31, 2020.

 

When we use works like “we,” “us”, “our,” the “company” and words of the like, unless otherwise indicated, we are referring to the operations of us and our wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. (“Coeptis”).

 

Objective

 

The objective of our Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is to provide users of our financial statements with the following:

 

A narrative explanation from the perspective of management of our financial condition, results of operations, cash flows, liquidity and certain other factors that may affect future results;

 

Useful context to the financial statements; and

 

Information that allows assessment of the likelihood that past performance is indicative of future performance.

 

Our MD&A is provided as a supplement to, and should be read together with, our unaudited financial statements for the three months ended September 30, 2021 and 2020, and the nine months ended September 30, 2021 and 2020, included in Part I, Item 1 of this Form 10-Q.

 

Overview and Outlook

 

Coeptis Therapeutics, Inc. (“Coeptis Therapeutics”) is a holding company that conducts its current operations through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. (“Coeptis”). We are a pharmaceutical company which owns, acquires, and develops drug products and pharmaceutical technologies which offer improvements to current therapies. Our products and technologies are intended to be commercialized in the US and worldwide markets. Since Coeptis’ inception in 2017, it has acquired and commercialized two drug products for the U S market, which were approved as 505b2 applications. These anti-hypertension products were launched into the US market during 2020 through a marketing partner. At launch, the sales and promotional efforts were significantly impeded by the limitation of the global pandemic and as such, we are continually evaluating plans in 2021.As a result we have terminated both our license agreement and distribution agreement in regard to our Consensi product affective September 24th, 2021. Additionally, in an effort to better focus on other growth opportunities, we are winding down our focus on the Conjupri product. We also began the development of several ANDA products which we divested in 2019 to a larger generic pharmaceutical drug manufacturer, and have moved away from focusing on the commercialization of generic products. In early 2021, we entered into strategic partnerships to co-develop improved therapies for the auto-immune and oncology markets. Following the reverse merger transaction involving us and Coeptis, we continue to focus on identifying and investing resources into innovative products and technologies which we believe will significantly transform Coeptis’ current products and therapies.

 

 

 

 13 

 

 

During 2020 and continuing into 2021, Coeptis faced several operational challenges related to the COVID-19 global pandemic, which we continue to work to overcome. The launch of both 5050b2 products was impacted because of various COVID-19 limitations, most notably field sales personnel were not able to make healthcare provider visits in person; thereby limiting the awareness of the availability of these products. We explored and implemented several non-personal promotion efforts, but given the global limitations and dynamics, it was challenging to achieve expected sales.

 

In May 2021, we entered into two exclusive option agreements (the “CD38 Agreements”) relating to separate technologies designed to improve the treatment of CD38-related cancers (e.g., multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia) with VyGen-Bio, Inc. (“Vy-Gen”), a majority-owned subsidiary of Vycellix, Inc., a Tampa, Florida-based private, immuno-centric discovery life science company focused on the development of transformational platform technologies to enhance and optimize next-generation cell and gene-based therapies, including T cell and Natural Killer (NK) cell-based cancer therapies.

 

The CD38 Agreements relate to two separate Vy-Gen drug product candidates, as follows:

 

CD38-GEAR-NK. This Vy-Gen drug product candidate is designed to protect CD38+ NK cells from destruction by anti-CD38 monoclonal antibodies, or mAbs. CD38-GEAR-NK is an autologous, NK cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 mAbs. We believe CD38-GEAR-NK possesses the potential to minimize the risks and side effects from CD38-positive NK cell fratricide.

 

Market Opportunity. We believe CD38-GEAR-NK could potentially revolutionize how CD38-related cancers are treated, by protecting CD38+ NK cells from destruction by anti-CD38 mAbs, thereby promoting the opportunity to improve the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.

 

Multiple myeloma is expected to be the first cancer indication targeted with CD38-GEAR-NK. The global multiple myeloma market was $19.48B in 2018 and is expected to reach $31B by 2026 [Source: Fortune Business Reports].

 

CD38-Diagnostic. This Vy-Gen product candidate is an in vitro diagnostic tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. CD38-Diagnostic is an in vitro screening tool that provides the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK. CD38-Diagnostic also has the potential to develop as a platform technology beyond CD38, to identify patients likely to benefit for broad range of mAb therapies across myriad indications.

 

Market Opportunity. We believe CD38-Diagnostic provides opportunity to make more cost-effective medical decisions for the treatment of B cell malignancies with high CD38 expression, including multiple myeloma, which may help to avoid unnecessary administration of anti-CD38 therapies. CD38-Diagnostic could prevent patients from being subjected to ineffective therapy and enable significant savings to healthcare systems.

 

CD38-Diagnostic could be offered as a companion diagnostic for determining patient suitability and likelihood of positive treatment outcomes for CD38-GEAR-NK and/or CD38 monoclonal antibody therapies.

 

GEAR-NK Product Overview. GEAR-NK is an autologous, gene-edited, natural killer cell-based therapeutic development platform that allows for modified NK cells to be co-administered with targeted mAbs, which, in the absence of the GEAR-NK, would otherwise be neutralized by mAb therapy.

 

Terms of the CD38 Agreements. In May 2021, we made initial payments totaling $750,000 under the CD38 Agreements, to acquire the exclusive options to acquire co-development rights with respect to CD38-GEAR-NK and CD38-Diagnostic. In August 2021, we entered into amendments to each of the CD38 Agreements. In connection with such amendments, we delivered promissory notes aggregating $3,250,000, with maturity dates of December 31, 2021. In connection with the two amendments, we plan to pay a cash payment of $1,000,000, and thereby be deemed to have exercised the two options. A portion of the proceeds from this offering are to apply to the payments owed to Vy-Gen. (See “Use of Proceeds”).

 

 

 

 14 

 

 

In the event that the promissory notes are timely paid by December 31, 2021, we will maintain our 50% ownership interest in CD38-GEAR-NK and CD38-Diagnostic, and, if the promissory notes are not timely paid by December 31, 2021, our ownership interest in CD38-GEAR-NK and CD38-Diagnostic will automatically be reduced to 20%, in which case the two promissory notes will be automatically cancelled and will no longer be due or payable.

 

Statera BioPharma. Coeptis executed a binding Letter of Intent (LOI) with Statera BioPharma, a clinical stage biopharmaceutical company developing immunotherapy via its proprietary AIMS platform. The LOI details a collaboration between the two companies for STAT-201, a product in development for Crohn’s disease. Coeptis is to assist Statera BioPharma in its efforts to develop and commercialize STAT-201 in adult and pediatric populations. Coeptis is to receive development fees and commercial milestones under the to-be-completed definitive agreement.

 

STAT-201. STAT-201 is a lower dose version of an existing FDA approved product. STAT-201 has been granted Orphan Drug designation by the FDA which provides up to 7 years of market exclusivity upon approval. The safety profile of STAT-201 has been established and clinical studies have been previously conducted showing preliminary efficacy in Crohn’s disease and other inflammatory diseases. A method of use patent was filed in 2011 and additional patents have been recently filed.

 

Development Strategy. Statera BioPharma is planning to initiate a 12-week, phase 3 clinical study in pediatric Crohn’s patients by year-end 2021. Upon successful completion of the study, Statera BioPharma plans to file a new drug application (NDA) with the FDA. Additional studies intended to expand the indication to pediatric Crohn’s disease are planned after approval.

 

Market Opportunity. There are many FDA approved products to treat Crohn’s disease, including aminosalicylates, such as Azulfidine® and Asacol®, corticosteroids and biologics, such as Humira®. Some of the disadvantages of current therapies include: high cost, frequent dosing (up to 3 doses per day) and side effects ranging from upper respiratory infection, risk of other infections, decreased immune system function, and diarrhea. In initial studies, STAT-201 exhibited mild side effects including vivid dreams, dizziness and headaches. STAT-201 will be available as an oral tablet or capsule taken once per day.

 

The United States market for Crohn’s disease was forecasted to be $6 Billion by 2021 [Source: Datamonitor Healthcare 2016]. A large portion of this market, approximately 60%, are the biologic drugs. It is estimated that up to 40% of Crohn’s patients may be non-responsive to biologic treatments. The target market for STAT-201 includes patients who do not tolerate and/or are considered non-responsive to biologic treatment. The market potential for STAT-201 in Crohn’s disease alone is approximately $1.4-2.4 Billion annually in the United States.

 

Vici Health Sciences, LLC. In partnership with Vici Health Sciences, LLC (“Vici”), we are co-developing a drug product, CPT60621 – a focus on Parkinson’s Disease. Through this partnership, Vici and Coeptis would co-develop, seek FDA approval and share ownership rights to CPT60621.

 

CPT60621 – a focus on Parkinson’s Disease. CPT60621 is a novel, ready to use, easy to swallow, oral liquid version of an already approved drug used for the treatment of Parkinson’s Disease (PD). The currently approved dosage form is only available as an oral solid tablet which can be difficult to swallow for some PD patients. Per Symphony Health data, an estimated 555,000 prescriptions are dispensed per year for the oral solid tablet version alone.

 

PD affected nearly 1,000,000 people in the U.S. in 2020, and nearly 10,000,000 people worldwide. Experts also predict that the PD affected rate is expected to increase at a rate of 2.2% per year for the next 10 years. The direct medical cost to treat PD is estimated to be over $25 billion per year, in which $4.1 billion of that is in medication cost alone.

 

Typical PD symptoms include thinking difficulties, uncontrolled shaking and tremors, loss of automatic movements, rigidity, and eating, speaking, and swallowing difficulties. During the course of their disease, nearly 80% of PD patients will develop a condition known as dysphagia which is defined as difficulty or discomfort in swallowing. Oral liquid dosage forms are easier to swallow than oral solid dosage forms. PD patients who suffer from dysphagia often must crush and dissolve tablets in juice in order to consume their medication. In more extreme cases, feeding tubes are utilized. This is costly to the healthcare system and is simply impractical.

 

 

 

 15 

 

 

CPT60621 can be administered to the patient using an easy-to-use oral syringe, eliminating time consuming, costly, and uncontrolled tablet crushing. This novel dosage form, if approved, we believe will fulfill a market need and provide a beneficial treatment option for many PD patients.

 

To date, Coeptis has completed proof-of-concept formulation work for CPT60621 and performed a pilot bioequivalence study with passing results. We are currently targeting a 2022 NDA filing and 2023 commercial launch. We have yet to determine whether a commercial launch, assuming FDA approval of the product, will be performed through internal commercialization efforts, or by establishing out-licensing arrangements or other strategic relationships. Coeptis and Vici are currently in discussions as to how to maximize the value of CPT60621.

 

We expect to generate revenue from product sales and technology licensing. We cannot be certain of the timing of this revenue and will likely need funding to support continuing operations and support our growth strategy. We may have to finance operations by offering any combination of equity offerings, debt financing, collaborations, strategic alliances, or other licensing arrangements.

 

Our Results of Operations

 

Revenue. To date, we have generated minimal revenue mostly from consulting arrangements and product sales. Due to the COVID-19 global pandemic and the resulting market dynamics, it is uncertain if the current marketed products can generate sufficient sales to cover expenses. If our strategic business discussions progress to agreements, we expect to generate additional revenue from collaboration partners.

 

Operating Expenses. General and administrative expenses consist primarily of salaries and related costs for personnel and professional fees for consulting services related to regulatory, pharmacovigilance, quality, legal, and business development. We expect that our general and administrative expenses will increase in the future as we increase our headcount to support the business growth. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, insurance, and investor relation expenses associated with operating as a public company.

 

Research and developments costs will continue to be dependent on the strategic business collaborations and agreements will are anticipating in the future.

 

We expect development costs to increase to support our new strategic initiatives.

 

Comparison of the three months ended September 30, 2021 and Septermber 30, 2020

 

Revenues. Revenues, which were generated from product sales of $0 and $9,888 recorded in the three months ended September 30, 2021 and 2020 respectively, continue to be minimal. The Company’s activities primarily include product development, raising capital, and building infrastructure. Management does not expect the Company to generate any significant revenue for at least the next two years, during which time drug development will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Company’s target products or technologies.

 

Operating Expenses

 

Overview. Operating expenses increased from $1,609,097 in the three months ended September 30, 2020 to $6,947,899 in the three months ended September 30, 2021.

 

The increase is mainly due to higher professional services fees, as well as new requirements for D&O insurance.

 

General and Administrative Expenses. For the three months ended September 30, 2020 and 2021, general and administrative expenses are included in operating expenses. All costs incurred can be attributed to the planned principal operations of product development, raising capital, and building infrastructure. Management may separate out G&A expenses in 2021 and 2022, especially if new personnel are hired consistent with the Company’s financial regulatory and filings obligations as a publicly traded entity.

 

 

 

 16 

 

 

Interest Expense. Interest expense was $183,871 for the three months ended September 30, 2020 and was $188,559 for the three months ended September 30, 2021. Interest was related to notes payable, which are discussed in detail in the Footnotes to the financial statements, incorporated by reference herein. Management expects that in 2021 and thereafter, interest expense will increase, as it may take on debt from insiders or independent third parties to fund operations either while awaiting receipt of the proceeds of equity capital financings or as a stand-alone strategy in addition to raising capital through equity capital financings.

 

Financial Resources and Liquidity. The Company had limited financial resources during the twelve months ended December 31, 2020, with cash and cash equivalents of just $202,965. For the period ending September 30, 2021, cash and cash equivalents increased to $2,809,861 as the Company raised capital in conjunction with its private placement and merger transaction. During both these time periods, the Company continues to operate a minimal infrastructure in order to maintain its ability to fund operations, keep full focus on all product development targets and to stay current with all of the Company’s scientist consultants, legal counsel, and accountants. During 2021, the Company believes that the ability to raise capital through equity transactions will increase liquidity and enable the execution of management’s operating strategy.

 

Comparison of the nine months ended September 30, 2021 and September 30, 2020

 

Revenues. Revenues, which were generated from consulting agreements of $75,000 for the nine months ended September 30, 2021 and $30,761 for the nine months ended September 30, 2020. The Company’s activities primarily include product development, raising capital, and building infrastructure. Management does not expect the Company to generate any significant revenue for at least the next two years, during which time drug development will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Company’s target products or technologies.

 

Operating Expenses

 

Overview. Operating expenses increased from $2,704,094 in the nine months ended September 30, 2020 to $ 11,347,048 in the nine months ended June 30, 2021. The increase is mainly due to higher professional services related to the merger transaction, as well as new requirements for D&O insurance.

 

General and Administrative Expenses. For the nine months ended September 30, 2020 and 2021, general and administrative expenses are included in operating expenses. All costs incurred can be attributed to the planned principal operations of product development, raising capital, and building infrastructure. Management may separate out G&A expenses in 2021 and 2022, especially if new personnel are hired consistent with the Company’s financial regulatory and filings obligations as a publicly traded entity.

 

Interest Expense. Interest expense was $266,382 and $262,826 for the nine months ended September 30, 2021 and 2020, respectively. Interest was related to notes payable, which are discussed in detail in the Footnotes to the financial statements, incorporated by reference herein. Management expects that in 2021 and thereafter, interest expense will increase, as it may take on debt from insiders or independent third parties to fund operations either while awaiting receipt of the proceeds of equity capital financings or as a stand-alone strategy in addition to raising capital through equity capital financings.

 

Item 3.Quantitative and Qualitative Disclosures about Market Risk

 

The Company is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information under this Item.

 

Item 4.Controls and Procedures

 

Disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

 

 

 17 

 

 

Our management, with the participation of our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer) evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Report on Form 10-Q. Based upon that evaluation, and as a result of the material weaknesses described below, our principal executive officer and principal financial officer concluded that, as of September 30, 2021, our disclosure controls and procedures were not effective. Management anticipates that such disclosure controls and procedures will not be effective until the material weaknesses are remediated.

 

Our Annual Report on Form 10-K contains information regarding a material weakness in our internal control over financial reporting as of December 31, 2020. For example, the Company lacked adequate segregation of duties which led to situations where individuals had access to both initiate and approve transactions with no additional formal review process.

 

In an effort to address the Company’s internal accounting personnel deficiencies, in February 2021 we hired a consulting group to assist our Chief Financial Officer. Accordingly, the Company believes, based on its knowledge, that: (i) this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading with respect to the period covered by this report; and (ii) the financial statements, and other financial information included in this quarterly report, fairly present in all material respects our financial condition, results of operations and cash flows as of and for the periods presented in this quarterly report.

 

 

 

 

 

 

 

 

 18 

 

 

PART II — OTHER INFORMATION

 

Item 1.Legal Proceedings

 

None.

 

Item 1A.Risk Factors

 

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Transition Report on Form 10-KT for the ten-months ended December 31, 2020, which could materially affect our business, financial condition or future results. The risks described in our Transition Report on Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

 

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

 

During the three months ended September 30, 2021, we issued 2,110,329 shares of our common stock in connection with a private offering of our common stock.

 

These shares were issued in reliance upon an exemption from registration provided by Section 506(b) of Regulation D.

 

We have previously disclosed all other sales of securities without registration under the Securities Act of 1933, as amended.

 

Item 3.Defaults Upon Senior Securities

 

Not applicable.

 

Item 4.Mine Safety Disclosures

 

Not applicable.

 

Item 5.Other Information

 

None.

 

Item 6.Exhibits

 

The following exhibits are attached hereto or incorporated by reference herein (numbered to correspond to Item 601(a) of Regulation S-K, as promulgated by the Securities and Exchange Commission) and are filed as part of this Form 10-Q:

 

31.1 Rule 13a-14(a)/15(d)-14(a) Certification of Chief Executive Officer, Principal Executive Officer. Filed herewith.
31.2 Rule 13a-14(a)/15(d)-14(a) Certification of President, Principal Financial Officer. Filed herewith.
32.1 Section 1350 Certification of Principal Executive Officer. Filed herewith.
32.2 Section 1350 Certification of Principal Financial Officer. Filed herewith.
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded
  within the Inline XBRL document)
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

 

 

 

 19 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    COEPTIS THERAPEUTICS, INC.
    Registrant
     
 Date: November 15, 2021  By: /s/ David Mehalick
    David Mehalick
    Chief Executive Officer, Principal Executive Officer
     
     
 Date: November 15, 2021  By: /s/ Christine Sheehy
    Christine Sheehy
    Chief Financial Officer, Principal Financial an Accounting Officer

 

 

 

 

 

 

 

 

 20 

 

EX-31.1 2 coeptis_ex3101.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATIONS PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Mehalick, certify that:

 

1.       I have reviewed this quarterly report on Form 10-Q of Coeptis Therapeutics, Inc. (the “Registrant”);

 

2.       Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4.       The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f)) for the Registrant and have:

 

a)       designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)       designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)        evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)        disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

 

5.       The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent functions):

 

a)       all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)       any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

 

Date: November 15, 2021 /s/ David Mehalick
  David Mehalick
  Chief Executive Officer, and Principal Executive Office

 

EX-31.2 3 coeptis_ex3102.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATIONS PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Christine Sheehy, certify that:

 

1.       I have reviewed this quarterly report on Form 10-Q of Coeptis Therapeutics, Inc. (the “Registrant”);

 

2.       Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4.       The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f)) for the Registrant and have:

 

a)       designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)       designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)        evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)        disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

 

5.       The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent functions):

 

a)       all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)       any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: November 15, 2021 /s/ Christine Sheehy
  Christine Sheehy
  Chief Financial Officer, and Principal Financial and Accounting Officer

 

EX-32.1 4 coeptis_ex3201.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report on Form 10-Q for the period ended September 30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 15, 2021 /s/ David Mehalick
  David Mehalick
  Chief Executive Officer, and Principal Executive Officer

 

EX-32.2 5 coeptis_ex3202.htm CERTIFICATION

EXHIBIT 32.2

 

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report on Form 10-Q for the period ended September 30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 15, 2021 /s/ Christine Sheehy
  Christine Sheehy
  Chief Financial Officer, and Principal Financial and Accounting Officer

 

EX-101.SCH 6 coep-20210930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LICENSE RIGHT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - CAPITAL STRUCTURE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - ASSET PURCHASE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 401(k) PROFIT-SHARING PLAN link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - LICENSE RIGHT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - LONG-TERM DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - CAPITAL STRUCTURE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 coep-20210930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 coep-20210930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 coep-20210930_lab.xml XBRL LABEL FILE Product and Service [Axis] Consulting Services [Member] Other Sales [Member] Equity Components [Axis] Preferred Stock Series B [Member] Common Stock [Member] Additional Paid-in Capital [Member] Common Stock Subscribed [Member] Retained Earnings [Member] Finite-Lived Intangible Assets by Major Class [Axis] Consensi License Right [Member] Vy Gen Options [Member] Counterparty Name [Axis] VyGen-Bio [Member] Long-term Debt, Type [Axis] Note Payable [Member] Note Payable 1 [Member] Note Payable 2 [Member] Note Payable 3 [Member] Note Payable 4 [Member] Note Payable 5 [Member] Note Payable 6 [Member] Note Payable 7 [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] License Agreement [Member] Related Party [Axis] Purple Bio Tech [Member] PPP Loan [Member] EIDL Loan [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series B Preferred Stock [Member] Coral Investment Partners [Member] Warrant Class A [Member] Warrant Class B [Member] Warrant Holder [Member] Common Stock Warrants [Member] Warrant Holder 1 [Member] Warrant Holder 2 [Member] Transaction Type [Axis] Asset Purchase Agreement [Member] Ani Pharmaceuticals [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Accounts receivable Inventories TOTAL CURRENT ASSETS PROPERTY AND EQUIPMENT Furniture and fixtures Less: accumulated depreciation Furniture and fixtures, net OTHER ASSETS Co-development options Right-of-use asset, net of accumulated amortization Other assets Total other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) CURRENT LIABILITIES Accounts payable Accrued expenses Notes payable, current portion Notes payable, related parties, current portion Right of use liability, current portion Deferred revenue TOTAL CURRENT LIABILITIES LONG TERM LIABILITIES Note payable Right of use liability, non-current portion TOTAL LONG TERM LIABILITIES TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES (NOTE 7) STOCKHOLDERS' EQUITY (DEFICIT) Series B Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, 8,000 and -0- shares issued and outstanding, respectively Common stock, $0.0001 par value, 750,000,000 shares authorized, 34,750,733 and 25,178,840 shares issued and outstanding, respectively Additional paid-in capital Common stock subscribed Accumulated deficit TOTAL STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] SALES Total sales Cost of goods, including inventory obsolescence Gross profit COST OF OPERATIONS Research and development General and administrative expenses Selling and marketing Interest expense Total operating expenses LOSS FROM OPERATIONS OTHER INCOME (EXPENSE) Royalties and licensing fees Other Income Gain (Loss) on write down of assets TOTAL OTHER INCOME (EXPENSE) LOSS BEFORE INCOME TAXES PROVISION FOR INCOME TAXES (BENEFIT) NET LOSS LOSS PER SHARE Loss per share, basic and fully diluted Weighted average number of common shares outstanding Beginning balance, value Balance at beginning, shares Retroactive application of recapitalization Retroactive application of recapitalization, shares Adjusted balance, beginning of period Adjusted balance, beginning of period, Shares Shares issued for cash Shares issued for cash, shares Shares issued for services Shares issued for services, shares Warrants issued for services Net income (loss) [custom:WarrantsIssuedForServices] Shares issued through conversion of debt Shares issued through conversion of debt, Shares Stock based compensation Ending balance, value Balance at ending, shares Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities: Depreciation and amortization Forgiveness of debt Interest paid Shares issued for non-employee services Warrants issued for services Stock based compensation Shares issued for conversion of debt Increase (decrease) in: Accounts receivable Inventories Right of use asset/liability Accounts payable Accrued expenses Deferred revenue NET CASH USED IN OPERATING ACTIVITIES INVESTING ACTIVITIES Purchase of license right Purchase of property and equipment NET CASH USED IN INVESTING ACTIVITIES FINANCING ACTIVITIES Proceeds from notes payable Proceeds from notes payable, related parties Repayment of notes payable Repayment of notes payable, related parties Shares from merger transaction Shares issued for cash Cash received for stock subscription NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE IN CASH CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD SUPPLEMENTAL DISCLOSURES Taxes paid (refunded) Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Goodwill and Intangible Assets Disclosure [Abstract] LICENSE RIGHT Debt Disclosure [Abstract] LONG-TERM DEBT Equity [Abstract] CAPITAL STRUCTURE Asset Purchase Agreement ASSET PURCHASE AGREEMENT Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Retirement Benefits [Abstract] 401(k) PROFIT-SHARING PLAN Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENT Principles of Consolidation Use of Estimates Accounting for non-employee share-based payments Adoption of New Accounting Pronouncements LONG-TERM DEBT Schedule of future minimum rental payments Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] License right Amortization expense Issuance of convertible debt Payments to Acquire Intangible Assets Notes Issued Debt Instrument, Maturity Date 2022 2023 2024 2025 Thereafter Total long-term debt Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Principal amount Debt stated interest rate Debt maturity date Note payable Debt interest rate increase if in default Debt Instrument, Interest Rate During Period Debt Instrument, Convertible, Conversion Price Accrued interest Proceeds from loan Debt Instrument, Decrease, Forgiveness Schedule of Stock by Class [Table] Class of Stock [Line Items] Number of share issued Additional paid in capital Capital distributions Warrants outstanding Warrant exercise price Warrant expiration date Offsetting Assets [Table] Offsetting Assets [Line Items] Revenue recognized from assets sale 2021 (remaining 3 months) 2022 Operating lease expense Royalty payable Proceeds from royalties Employer contribution Income tax expense benefit Retroactive application of recapitalization, shares Assets, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Other Assets Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Attributable to Parent Shares, Outstanding Gain (Loss) on Extinguishment of Debt Share-based Payment Arrangement, Noncash Expense SharesIssuedForConversionOfDebt Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable SharesFromMergerTransaction Proceeds from Issuance of Common Stock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Schedule of Maturities of Long-term Debt [Table Text Block] Long-term Debt Notes Payable Operating Leases, Future Minimum Payments, Due in Two Years EX-101.PRE 10 coep-20210930_pre.xml XBRL PRESENTATION FILE XML 11 coeptis_i10q-093021_htm.xml IDEA: XBRL DOCUMENT 0001819663 2021-01-01 2021-09-30 0001819663 2021-11-15 0001819663 2021-09-30 0001819663 2020-12-31 0001819663 2021-07-01 2021-09-30 0001819663 2020-07-01 2020-09-30 0001819663 2020-01-01 2020-09-30 0001819663 coep:ConsultingServicesMember 2021-07-01 2021-09-30 0001819663 coep:ConsultingServicesMember 2020-07-01 2020-09-30 0001819663 coep:ConsultingServicesMember 2021-01-01 2021-09-30 0001819663 coep:ConsultingServicesMember 2020-01-01 2020-09-30 0001819663 coep:OtherSalesMember 2021-07-01 2021-09-30 0001819663 coep:OtherSalesMember 2020-07-01 2020-09-30 0001819663 coep:OtherSalesMember 2021-01-01 2021-09-30 0001819663 coep:OtherSalesMember 2020-01-01 2020-09-30 0001819663 coep:PreferredStockSeriesBMember 2019-12-31 0001819663 us-gaap:CommonStockMember 2019-12-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001819663 coep:CommonStockSubscribedMember 2019-12-31 0001819663 us-gaap:RetainedEarningsMember 2019-12-31 0001819663 2019-12-31 0001819663 coep:PreferredStockSeriesBMember 2020-01-01 2020-03-31 0001819663 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001819663 coep:CommonStockSubscribedMember 2020-01-01 2020-03-31 0001819663 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001819663 2020-01-01 2020-03-31 0001819663 coep:PreferredStockSeriesBMember 2020-03-31 0001819663 us-gaap:CommonStockMember 2020-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001819663 coep:CommonStockSubscribedMember 2020-03-31 0001819663 us-gaap:RetainedEarningsMember 2020-03-31 0001819663 2020-03-31 0001819663 coep:PreferredStockSeriesBMember 2020-04-01 2020-06-30 0001819663 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001819663 coep:CommonStockSubscribedMember 2020-04-01 2020-06-30 0001819663 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001819663 2020-04-01 2020-06-30 0001819663 coep:PreferredStockSeriesBMember 2020-06-30 0001819663 us-gaap:CommonStockMember 2020-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001819663 coep:CommonStockSubscribedMember 2020-06-30 0001819663 us-gaap:RetainedEarningsMember 2020-06-30 0001819663 2020-06-30 0001819663 coep:PreferredStockSeriesBMember 2020-07-01 2020-09-30 0001819663 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001819663 coep:CommonStockSubscribedMember 2020-07-01 2020-09-30 0001819663 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001819663 coep:PreferredStockSeriesBMember 2020-09-30 0001819663 us-gaap:CommonStockMember 2020-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001819663 coep:CommonStockSubscribedMember 2020-09-30 0001819663 us-gaap:RetainedEarningsMember 2020-09-30 0001819663 2020-09-30 0001819663 coep:PreferredStockSeriesBMember 2020-12-31 0001819663 us-gaap:CommonStockMember 2020-12-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001819663 coep:CommonStockSubscribedMember 2020-12-31 0001819663 us-gaap:RetainedEarningsMember 2020-12-31 0001819663 coep:PreferredStockSeriesBMember 2021-01-01 2021-03-31 0001819663 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001819663 coep:CommonStockSubscribedMember 2021-01-01 2021-03-31 0001819663 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001819663 2021-01-01 2021-03-31 0001819663 coep:PreferredStockSeriesBMember 2021-03-31 0001819663 us-gaap:CommonStockMember 2021-03-31 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001819663 coep:CommonStockSubscribedMember 2021-03-31 0001819663 us-gaap:RetainedEarningsMember 2021-03-31 0001819663 2021-03-31 0001819663 coep:PreferredStockSeriesBMember 2021-04-01 2021-06-30 0001819663 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001819663 coep:CommonStockSubscribedMember 2021-04-01 2021-06-30 0001819663 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001819663 2021-04-01 2021-06-30 0001819663 coep:PreferredStockSeriesBMember 2021-06-30 0001819663 us-gaap:CommonStockMember 2021-06-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001819663 coep:CommonStockSubscribedMember 2021-06-30 0001819663 us-gaap:RetainedEarningsMember 2021-06-30 0001819663 2021-06-30 0001819663 coep:PreferredStockSeriesBMember 2021-07-01 2021-09-30 0001819663 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001819663 coep:CommonStockSubscribedMember 2021-07-01 2021-09-30 0001819663 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001819663 coep:PreferredStockSeriesBMember 2021-09-30 0001819663 us-gaap:CommonStockMember 2021-09-30 0001819663 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001819663 coep:CommonStockSubscribedMember 2021-09-30 0001819663 us-gaap:RetainedEarningsMember 2021-09-30 0001819663 coep:ConsensiLicenseRightMember 2021-09-30 0001819663 coep:ConsensiLicenseRightMember 2020-12-31 0001819663 coep:VyGenOptionsMember 2021-01-01 2021-05-06 0001819663 coep:VyGenMember 2020-10-01 2021-08-15 0001819663 coep:NotePayableMember 2021-09-30 0001819663 coep:NotePayableMember 2021-01-01 2021-09-30 0001819663 coep:NotePayable1Member 2020-12-31 0001819663 coep:NotePayable2Member 2021-09-30 0001819663 coep:NotePayable2Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable2Member 2020-12-31 0001819663 coep:NotePayable3Member 2021-09-30 0001819663 coep:NotePayable3Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable3Member 2020-12-31 0001819663 coep:NotePayable4Member 2021-09-30 0001819663 coep:NotePayable4Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable4Member 2020-12-31 0001819663 coep:NotePayable5Member 2021-09-30 0001819663 coep:NotePayable5Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable5Member 2020-12-31 0001819663 coep:NotePayable6Member 2021-09-30 0001819663 coep:NotePayable6Member 2021-01-01 2021-09-30 0001819663 coep:NotePayable6Member 2020-12-31 0001819663 coep:NotePayable7Member 2021-09-30 0001819663 coep:NotePayable7Member 2020-12-31 0001819663 coep:PurpleBioTechMember coep:LicenseAgreementMember 2021-09-30 0001819663 coep:PurpleBioTechMember coep:LicenseAgreementMember 2021-01-01 2021-09-30 0001819663 coep:PppLoanMember 2020-01-01 2020-05-06 0001819663 coep:PppLoanMember 2021-01-01 2021-02-28 0001819663 coep:PppLoanMember 2021-09-30 0001819663 coep:PppLoanMember 2020-12-31 0001819663 coep:EidlLoanMember 2020-01-01 2020-07-08 0001819663 coep:EidlLoanMember 2020-07-08 0001819663 coep:EidlLoanMember 2021-09-30 0001819663 coep:EidlLoanMember 2020-12-31 0001819663 us-gaap:CommonStockMember 2021-09-30 0001819663 us-gaap:CommonStockMember 2020-09-30 0001819663 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001819663 coep:SeriesBConvertiblePreferredStockMember 2021-09-30 0001819663 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001819663 coep:CoralInvestmentPartnersMember coep:WarrantClassAMember 2020-11-23 0001819663 coep:CoralInvestmentPartnersMember coep:WarrantClassBMember 2020-11-23 0001819663 coep:WarrantHolderMember coep:CommonStockWarrantsMember 2021-05-28 0001819663 coep:WarrantHolder1Member coep:CommonStockWarrantsMember 2021-05-28 0001819663 coep:WarrantHolder2Member coep:CommonStockWarrantsMember 2021-05-28 0001819663 coep:WarrantHolderMember coep:CommonStockWarrantsMember 2021-07-30 0001819663 coep:WarrantHolder1Member coep:CommonStockWarrantsMember 2021-07-30 0001819663 coep:WarrantHolder2Member coep:CommonStockWarrantsMember 2021-07-30 0001819663 coep:AniPharmaceuticalsMember coep:AssetPurchaseAgreementMember 2019-01-01 2019-06-18 iso4217:USD shares iso4217:USD shares pure 0001819663 false Q3 2021 --12-31 10-Q true 2021-09-30 false 000-56194 Coeptis Therapeutics, Inc. DE 84-3998117 105 Bradford Rd Suite 420 Wexford PA 15090 (724) 934-6467 Yes Yes Non-accelerated Filer true true false false 36441999 2809861 202965 26302 21786 0 0 2836164 224751 25237 25237 10944 9730 14293 15507 4804167 0 28352 58225 0 2000 4832519 60225 7682976 300484 1281314 1623840 153811 732146 3999595 1277500 0 604000 10758 41618 0 1000000 5445478 5279104 1650000 150000 14723 14723 1664723 164723 7110201 5443827 0.0001 0.0001 10000000 10000000 8000 8000 0 0 1 0 0.0001 0.0001 750000000 750000000 34750733 34750733 25178840 25178840 3317 2519 23902974 8954985 1377000 0 -24710518 -14100846 572774 -5143342 7682976 300484 0 9888 75000 30761 0 0 0 0 0 9888 75000 30761 0 1492 0 3361 0 8396 75000 27400 0 0 0 3543 6759339 1433621 11077747 2437725 0 0 2918 0 188559 183871 266382 262826 6947898 1617492 11347048 2704094 -6947898 -1609097 -11272048 -2676694 3543 -211550 -413124 -1711550 0 0 77500 0 -2000 0 -2000 0 1001543 -211550 662376 -1711550 -5946356 -1820647 -10609672 -4388244 0 0 0 0 -5946356 -1820647 -10609672 -4388244 -0.17 -0.09 -0.34 -0.23 34060556 20164597 31054813 18756999 16196000 1620 5464465 100000 -4944559 621526 1588800 -297949 -297949 17784800 1620 5166516 100000 -4944559 323577 200000 20 99980 -100000 -1896399 -1896399 17984800 1640 5266496 -6840958 -1572822 667840 67 333853 333920 -685254 -685254 18652640 1707 5600349 -7526212 -1924156 3300000 330 649670 100000 750000 -1820647 -1820647 21952640 2037 6250019 100000 -9346859 -2994803 25178840 2519 8954985 -14100846 -5143342 8000 1 1589400 -298062 -298061 2436500 244 2436256 471000 2907500 770000 77 769923 770000 -1950081 -1950081 8000 1 29974740 2839 11863102 471000 -16050927 -3713985 1281664 128 1922368 -388500 1533996 690000 69 1034931 1035000 676892 676892 694000 69 1040931 1041000 -2713235 -2713235 8000 1 32640404 3106 16538223 82500 -18764162 -2140332 1705329 171 2557828 1294500 3852499 405000 41 607460 607500 2301879 2301879 1897585 1897585 -5946356 -5946356 8000 1 34750733 3317 23902975 1377000 -24710518 572774 -10609672 -4388244 1214 1444 77500 -0 0 0 2412500 333920 2978771 0 1897585 0 -1041000 -0 4516 14907 -0 1014659 -988 1945 -340621 1916183 -578335 112806 -1000000 500000 -4280561 -2551512 4804167 -0 -0 -0 -4804167 0 4827595 1227500 0 604000 527905 -0 -604000 0 298061 -0 6916994 650000 1377000 100000 11691623 2581500 2606897 29988 202965 440088 2809861 470076 0 0 0 0 <p id="xdx_806_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zAADUH9npE95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 – <span id="xdx_820_z639XNyXq4De">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nature of Business </b>– Coeptis Pharmaceuticals, LLC (LLC) was formed in July 12, 2017 as a Pennsylvania multi-member limited liability company. On December 1, 2018, the members of LLC contributed their interest to a newly formed corporation, Coeptis Pharmaceuticals, Inc (“Coeptis”). As of December 1, 2018, the LLC became a disregarded single-member limited liability company which is wholly owned by the newly formed corporation. On February 12, 2021, Vinings Holdings, Inc., a Delaware corporation (“Vinings”), merged (the “Merger”) with and into Coeptis Pharmaceuticals, Inc. On July 12, 2021, the company has legally changed its name from Vinings Holdings, Inc. to Coeptis Therapeutics, Inc. Coeptis was the surviving corporation of that Merger. As a result of the Merger, Vinings acquired the business of Coeptis and will continue the existing business operations of Coeptis as a wholly owned subsidiary. The Merger was treated as a recapitalization of the Company for financial accounting purposes. The historical financial statements of Vinings before the Merger were replaced with the historical financial statements of Coeptis before the Merger in all future filings with the Securities and Exchange Commission (the “SEC”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is located in Wexford, PA, and engages primarily in the acquisition, development, and commercialization of pharmaceutical products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation - </b>The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of September 30, 2021, along with its results of operations for the three and nine month periods ended September 30, 2021 and 2020 and cash flows for the nine-month periods ended September 30, 2021 and 2020. Interim financial statements are prepared on a basis consistent with the Company’s annual financial statements and should be read in conjunction with our Annual Report on Form 10-KT for the fiscal year ended December 31, 2020. Results of operations for the nine-month period ended September 30, 2021, are not necessarily indicative of the operating results that may be expected for the full year ending December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Merger, the financial statements included in this report reflect (1) the historical operating results of Coeptis prior to the Merger; (2) the combined results of the Company and Coeptis following the closing of the Merger; (3) the assets and liabilities of Coeptis at their historical cost; and (4) the Company’s equity structure for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties </b>- In late 2019, an outbreak of a novel strain of the Coronavirus 2019 Disease (COVID-19) was identified and infections have been found in a number of countries around the world, including the United States. COVID-19 and its impact on trade including customer demand, travel, employee productivity, supply chain, and other economic activities has had, and may continue to have, a potentially significant effect on financial markets and business activity. The extent of the impact of COVID-19 on the Company’s operational and financial performance is currently uncertain and cannot be predicted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zFVFVuN5trh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 – <span id="xdx_82F_z56O4MUpSde5">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s significant accounting policies are described in Note 2 “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-KT filed with the U.S. Securities and Exchange Commission (“SEC”) on May 11, 2021. There have been no material changes to the significant accounting policies during the period ended September 30, 2021, except for items mentioned below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zVYMqYdVige7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zyET6TYBhHbi">Principles of Consolidation</span> – </b>The accompanying unaudited condensed consolidated financial statements include the accounts of Coeptis Therapeutics Inc., Coeptis Pharmaceuticals, Inc. and its wholly-owned subsidiary, Coeptis Pharmaceuticals, LLC. All material intercompany accounts, balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_841_eus-gaap--UseOfEstimates_zztNeZSDhILj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_zuiVfnLV67wa">Use of Estimates</span> </b>– The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_842_ecustom--AccountingNonEmployeeShareBasedPaymentsPolicyTextBlock_zNdwT8YaB0yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_zHVYGQgZ0Iv7">Accounting for non-employee share-based payments</span> – </b>The Company may from time to time issue share based compensation to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to equity instruments for the settlement of services provided by non-employees is recorded on the statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. Warrants that provide the option to purchase common stock are accounted for in accordance with ASC 718-10-35-1D, where the total cost of the compensation is based on the number of instruments for which a service has been rendered, and recognized over the period that the service is performed. To determine the amount of compensation cost to be recognized in each period, the Company shall recognize the effect of forfeitures in compensation cost when they occur. Previously recognized compensation cost shall be reversed in the period that the award is forfeited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zGtHU57Zth6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zRtB9NvP9eR7"><b>Adoption of New Accounting Pronouncements</b></span> – In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30, 2021, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zVYMqYdVige7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zyET6TYBhHbi">Principles of Consolidation</span> – </b>The accompanying unaudited condensed consolidated financial statements include the accounts of Coeptis Therapeutics Inc., Coeptis Pharmaceuticals, Inc. and its wholly-owned subsidiary, Coeptis Pharmaceuticals, LLC. All material intercompany accounts, balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_841_eus-gaap--UseOfEstimates_zztNeZSDhILj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_zuiVfnLV67wa">Use of Estimates</span> </b>– The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_842_ecustom--AccountingNonEmployeeShareBasedPaymentsPolicyTextBlock_zNdwT8YaB0yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_866_zHVYGQgZ0Iv7">Accounting for non-employee share-based payments</span> – </b>The Company may from time to time issue share based compensation to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to equity instruments for the settlement of services provided by non-employees is recorded on the statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. Warrants that provide the option to purchase common stock are accounted for in accordance with ASC 718-10-35-1D, where the total cost of the compensation is based on the number of instruments for which a service has been rendered, and recognized over the period that the service is performed. To determine the amount of compensation cost to be recognized in each period, the Company shall recognize the effect of forfeitures in compensation cost when they occur. Previously recognized compensation cost shall be reversed in the period that the award is forfeited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zGtHU57Zth6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zRtB9NvP9eR7"><b>Adoption of New Accounting Pronouncements</b></span> – In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30, 2021, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_80D_eus-gaap--IntangibleAssetsDisclosureTextBlock_z1cieCGBwAzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 – <span id="xdx_824_zgsSXMFAgFdi">LICENSE RIGHT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2019, the Company entered into an agreement with a foreign entity to market, distribute, and sell the Consensi product (Product) on an exclusive basis within the United States and Puerto Rico. Upon execution of the Agreement the Company paid $1,000,000 to the foreign entity. Milestone payments were due as follows; (1) $1,500,000 upon completion of the CMC Plan as reimbursements of costs incurred by the foreign entity, (2) $1,000,000 was due upon first commercial sale of the Product which occurred in June 2020. Milestones were not met during nine months ended September 30, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fourth quarter of 2020, the Company determined that there was a reduction of the useful life of the asset, resulting in a full impairment of the asset. The carrying value of the license right at September 30, 2021 and December 31, 2020 was $<span id="xdx_906_eus-gaap--FiniteLivedContractualRightsGross_c20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ConsensiLicenseRightMember_pp0p0" title="License right"><span id="xdx_90D_eus-gaap--FiniteLivedContractualRightsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ConsensiLicenseRightMember_pp0p0" title="License right">0</span></span>. Amortization expenses total $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210930_pp0p0" title="Amortization expense">0</span> and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930_pp0p0" title="Amortization expense">0</span> for the nine months ended September 30, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September of 2021, the Company executed a license termination agreement with the foreign entity to cease all efforts for sales and promotion of the product in the United States and Puerto Rico. The termination included issuance of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20210101__20210930_ziWuXiLdBaw7" title="Issuance of convertible debt">1,500,000</span> of convertible debt due in 2023 to satisfy amounts owed for the license, issue of warrants (See NOTE 5) and transfer of inventory ownership back to the foreign entity. In conjunction with this termination, the Company also terminated its marketing agreement with a third party for the Product’s sales and promotion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2021, the Company made initial payments under two definitive agreements. The two definitive option purchase agreements are with VyGen-Bio, Inc. (“Vy-Gen”), pursuant to which the Company has the exclusive option to acquire co-development rights with respect to two Vy-Gen product candidates. The Company paid a total of $<span id="xdx_90B_eus-gaap--PaymentsToAcquireIntangibleAssets_c20210101__20210506__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--VyGenOptionsMember_pp0p0" title="Payments to Acquire Intangible Assets">750,000</span> to acquire the two exclusive options. On August 15, 2021, the Company entered into amendments to each of the two definitive option purchase agreements, in connection with such amendments the Company delivered promissory notes aggregating $<span id="xdx_905_eus-gaap--NotesIssued1_c20201001__20210815__srt--CounterpartyNameAxis__custom--VyGenMember_zIVUsyeizCWg">3,250,000</span> with maturity dates of <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20201001__20210815__srt--CounterpartyNameAxis__custom--VyGenMember_znopxTHakMx5">December 31, 2021</span>. In connection with the two amendments the Company plans to pay a cash payment of $1,000,000, and thereby the Company will be deemed to have exercised the two options. In the event that the promissory notes are timely paid by December 31, 2021, the Company will maintain its 50% ownership interest in the two Vy-Gen product candidates, and if the promissory notes are not timely paid by December 31, 2021 the Company’s ownership interest in such assets will automatically be reduced to 20%, in which case the two promissory notes will be automatically cancelled and will no longer be due or payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0 0 0 0 1500000 750000 3250000 2021-12-31 <p id="xdx_804_eus-gaap--LongTermDebtTextBlock_z7eDa23WEMZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4 – <span id="xdx_825_z7s5BMdEzUoh">LONG-TERM DEBT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a note payable agreement with an unrelated company with a conversion option. The principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_pp0p0" title="Principal amount">200,000</span>, which is unsecured, together with interest at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_zwChdoAqzKM4" title="Debt stated interest rate">9</span>% was due <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayableMember_zhqgL6Di92f" title="Debt maturity date">June 15, 2020</span>. In lieu of cash repayment, the outstanding principal amount of the note, plus all accrued unpaid interest may be converted at the option of the party, in whole or in part, into shares of Common Stock. As of the December 31, 2020, the note had a balance of $<span id="xdx_907_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable1Member_pp0p0" title="Note payable">200,000</span>. The note and accrued interest were paid in full in the first quarter of 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Principal amount">500,000</span>, which is secured by a security agreement, together with interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zcyB7kX9HAvi" title="Debt stated interest rate">8</span>%, plus additional <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zsXrR7WbVYaa" title="Debt interest rate increase if in default">2</span>% in the event of default, was due <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_zMioCOf6CeU9" title="Debt maturity date">February 8, 2021</span>. The balance of the note is $<span id="xdx_90D_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Note payable"><span id="xdx_904_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable2Member_pp0p0" title="Note payable">500,000</span></span> as of September 30, 2021 and December 31, 2020. This debt is currently in default.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the Company entered into a Senior Secured Note agreement with a related party stockholder. The principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Principal amount">250,000</span>, which is secured by a security agreement, together with interest at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_zeNnx8Z5CK5i" title="Debt stated interest rate">8</span>%, plus additional <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_zm764B14vy2b" title="Debt interest rate increase if in default">2</span>% in the event of default, was due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_zTUE5296R9rc" title="Debt maturity date">February 8, 2021</span>. This debt was converted to equity in June 2021. The balance of the note was $<span id="xdx_90C_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Note payable">0</span> and $<span id="xdx_905_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable3Member_pp0p0" title="Note payable">250,000</span> as of September 30, 2021 and December 31, 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the Company entered into another Senior Secured Note agreement with a stockholder. The principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Principal amount">250,000</span>, which is secured by a security agreement, together with interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_z6JU82aA16L3" title="Debt stated interest rate">8</span>%, plus additional <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_zPwM5xRy6nB1" title="Debt interest rate increase if in default">2</span>% in the event of default, was due <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_z9ZCmVbSeaX5" title="Debt maturity date">February 8, 2021</span>. This debt was converted to equity in June 2021. The balance of the note is $<span id="xdx_90F_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Note payable">0</span> and $<span id="xdx_909_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable4Member_pp0p0" title="Note payable">250,000</span> as of September 30, 2021 and December 31, 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_pp0p0" title="Principal amount">333,000</span>, which is secured by a security agreement, together with interest at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zvLhgLfLG6vj" title="Debt stated interest rate">8</span>%, plus additional <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zR1EdcjkS17k" title="Debt interest rate increase if in default">2</span>% in the event of default, was due <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_zXE2AySfN236" title="Debt maturity date">February 8, 2021</span>. This debt was converted to equity in June 2021. The balance of the note was $<span id="xdx_90E_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_pp0p0" title="Note payable">0</span> and $<span id="xdx_908_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable5Member_pp0p0" title="Note payable">333,000</span> as of September 30, 2021 and December 31, 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Principal amount">167,000</span>, which is secured by a security agreement, together with interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zAQZujk6o9rk" title="Debt stated interest rate">8</span>%, plus additional <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_ziuWstUXjLj9" title="Debt interest rate increase if in default">2</span>% in the event of default, was due <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_zloDgwrnhful" title="Debt maturity date">February 8, 2021</span>. The balance of the note is $<span id="xdx_901_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Note payable"><span id="xdx_90B_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable6Member_pp0p0" title="Note payable">167,000</span></span> as of September 30, 2021 and December 31, 2020. This debt is currently in default.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2020, the Company entered a non-interest bearing, unsecured note agreement with two shareholders for $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Principal amount">104,000</span> with an unspecified due date. The note was converted to equity in June 2021. The balance was $<span id="xdx_900_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Note payable">0</span> and $<span id="xdx_90A_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotePayable7Member_pp0p0" title="Note payable">104,000</span> as of September 30, 2021 and December 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, as part of a termination of license agreement with Purple BioTech, the Company issued a convertible note in the principle amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_dm_c20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zis2VhoMzLk2">1,500,000 that is p</span>ayable on or before February 2023, bearing interest of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zTWY0quC7CYc">5</span>% per annum and convertible in whole or in part at any time by Purple BioTech into shares of Coeptis’ common stock. The conversion price is $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PurpleBioTechMember_zQNwKeHw8OT3">5 </span>per share of common stock, subject to certain adjustments under such terms and conditions as agreed between the parties. Coeptis may prepay the principal amount of the Note plus accrued and unpaid interest at any time, prior to the Maturity Date. Inventory, which has been fully written-off on the Company’s balance sheet, will be transferred back to Purple at Purple’s cost.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest accrued on the related party notes at September 30, 2021 and December 31,2020 was $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210930_pp0p0" title="Accrued interest">0</span> and $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_c20201231_pp0p0" title="Accrued interest">40,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loans under the CARES Act </b>-- On May 6, 2020, the Company received loan proceeds in the amount of approximately $<span id="xdx_906_eus-gaap--ProceedsFromLoans_c20200101__20200506__us-gaap--LongtermDebtTypeAxis__custom--PppLoanMember_pp0p0" title="Proceeds from loan">77,500</span> under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. In February 2021, an additional $<span id="xdx_903_eus-gaap--ProceedsFromLoans_c20210101__20210228__us-gaap--LongtermDebtTypeAxis__custom--PppLoanMember_pp0p0" title="Proceeds from loan">77,595</span> was received by the Company under the second round of PPP (“PPP2”). The Company has used the proceeds for purposes consistent with its intended use. The initial loan was forgiven in the amount of $<span id="xdx_902_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210101__20210930_zmZBgbQqU5X7" title="Debt Instrument, Decrease, Forgiveness">77,500</span> in principal and $893.40 in interest on June 25, 2021. The Company applied for PPP2 loan forgiveness in September 2021 and received full forgiveness in October 2021. As of September 30, 2021, and December 31, 2020, the balance of the notes totaled $<span id="xdx_90F_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--PppLoanMember_pp0p0" title="Note payable">77,595</span> and $<span id="xdx_905_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--PppLoanMember_pp0p0" title="Note payable">77,500</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020 the Company received a loan of $<span id="xdx_90B_eus-gaap--ProceedsFromLoans_c20200101__20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_pp0p0" title="Proceeds from loan">150,000</span> from the from the United States Small Business Administration (the “SBA”) under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Proceeds are intended to be used for working capital purposes. Interest on the EIDL Loan accrues at the rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200708__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_zj3kShjKzkub" title="Debt stated interest rate">3.75</span>% per annum and installment payments, including principal and interest, are due monthly beginning July 2022 in the amount of $731. The balance of principal and interest is payable thirty years from the date of the promissory note. The balance of the loan is $<span id="xdx_906_eus-gaap--NotesPayable_c20210930__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_pp0p0" title="Note payable"><span id="xdx_900_eus-gaap--NotesPayable_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EidlLoanMember_pp0p0" title="Note payable">150,000</span></span>, as of September 30, 2021 and December 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Maturities of long-term debt for the quarter ended September 30, 2021 are as follows: </span></p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zz9MtQi8ulW2" style="background-color: White; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - LONG-TERM DEBT (Details)"> <tr style="vertical-align: bottom"> <td><span style="color: rgb(238,238,238); font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_49B_20210930_zAixYxzDJ3wi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_d0_maLTDz1qy_z4j4BGoOzSrd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz1qy_ztFVlfnzchdb" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">1,502,001</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz1qy_zvOqe4HxDfx6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,279</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz1qy_zOns3LDtEY6f" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_pp0p0_maLTDz1qy_zetOX88yYxz6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">134,038</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz1qy_zxtQTQzy9Pqa" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total long-term debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,650,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 200000 0.09 2020-06-15 200000 500000 0.08 0.02 2021-02-08 500000 500000 250000 0.08 0.02 2021-02-08 0 250000 250000 0.08 0.02 2021-02-08 0 250000 333000 0.08 0.02 2021-02-08 0 333000 167000 0.08 0.02 2021-02-08 167000 167000 104000 0 104000 0.05 5 0 40000 77500 77595 77500 77595 77500 150000 0.0375 150000 150000 <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zz9MtQi8ulW2" style="background-color: White; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - LONG-TERM DEBT (Details)"> <tr style="vertical-align: bottom"> <td><span style="color: rgb(238,238,238); font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_49B_20210930_zAixYxzDJ3wi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_d0_maLTDz1qy_z4j4BGoOzSrd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">–</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz1qy_ztFVlfnzchdb" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: left">2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">1,502,001</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz1qy_zvOqe4HxDfx6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,279</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz1qy_zOns3LDtEY6f" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_pp0p0_maLTDz1qy_zetOX88yYxz6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">134,038</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz1qy_zxtQTQzy9Pqa" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total long-term debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,650,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 1502001 5279 8682 134038 1650000 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwuT2VG4h0ac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 – <span id="xdx_82B_zrW4iImNFcVb">CAPITAL STRUCTURE</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total number of shares of stock which the corporation shall have authority to issue is <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210930_pdd" title="Number of share issued">760,000,000</span> shares, of which <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20210930_zmPanuaMdKcj" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_z1RqbH3dAbK9" title="Common stock, shares authorized">750,000,000</span></span> shares of $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210930_zRn0rEdD7fo4" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231_zj2p3fIhx543" title="Common stock, par value">0.0001</span></span> par value shall be designated as Common Stock and <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20210930_zCtkcMLFBBFg" title="Preferred stock, shares authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zyYRpkllQqeh" title="Preferred stock, shares authorized">10,000,000</span></span> shares of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210930_ze1RqPaWNRIh" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_z6yipqNs2J8" title="Preferred stock, par value">0.0001</span></span> shall be designated as Preferred Stock. The Preferred Stock authorized by these Articles of Incorporation may be issued in one or more series. The Board of Directors of the Corporation is authorized to determine or alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any series and to fix the numbers of shares of any series.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock - </b>As of September 30, 2021 the Company had <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zld0F5IfOyX" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zoDhUptRLrdc" title="Common stock, shares outstanding">34,750,733</span></span> shares of its common stock issued and outstanding, and on September 30, 2020 the Company had <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zVIVEdCBoaAj" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKXuZEStUrSb" title="Common stock, shares outstanding">21,952,640</span></span> shares of its common stock issued and outstanding. All references to the common shares outstanding have been retroactively adjusted to reflect the stock splits unless stated otherwise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021 and 2020, the Company raised capital by issuance of common stock above the stated par value. The contributed capital recognized as additional paid in capital during the nine months ended September 30, 2021 and 2020 was $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_pp0p0_c20210101__20210930_zO8ppUTNTty4" title="Additional paid in capital">13,064,256</span> and $<span id="xdx_901_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_pp0p0_c20200101__20200930_zHDa6PaUG9Ya" title="Additional paid in capital">5,952,069</span> respectively. During the nine months ended September 30, 2021 and 2020, there were $<span id="xdx_90F_ecustom--CapitalDistributions_c20210101__20210930_zGj4NdlmZEfj" title="Capital distributions"><span id="xdx_908_ecustom--CapitalDistributions_c20200101__20200930_zEr5PxLpEIF1" title="Capital distributions">0</span></span> in capital distributions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series A Preferred Stock - </b>As of April 30, 2019, the Series A Preferred Stock had been canceled, and no shares remain outstanding. The rights and privileges of future issuances of the Series A Preferred stock will be determined at such time if and when they are issued. As of September 30, 2021, there were <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares outstanding">0</span> shares of Series A Preferred outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series B Convertible Preferred Stock - </b>The Company designated <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_pdd" title="Preferred stock, shares authorized">2,000,000</span> shares of Series B Convertible Preferred Stock with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_pdd" title="Preferred stock, par value">0.0001</span> per share. Initially, there will be no dividends due or payable on the Series B Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All shares of the Series B Preferred Stock shall rank (i) senior to the Corporation’s Common Stock and any other class or series of capital stock of the Corporation hereafter created, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series B Preferred Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series B Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series B Preferred shall have no liquidation preference over any other class of stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each holder of outstanding shares of Series B Preferred Stock shall be entitled to the number of votes equal to equal to one thousand (1,000) Common Shares. Except as provided by law, or by the provisions establishing any other series of Preferred Stock, holders of Series B Preferred Stock and of any other outstanding series of Preferred Stock shall vote together with the holders of Common Stock as a single class.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each holder of shares of Series B Preferred Stock may, at any time and from time to time, convert (an “Optional Conversion”) each of its shares of Series B Preferred Stock into a 1,000 of fully paid and nonassessable shares of Common Stock; provided, however, that any Optional Conversion must involve the issuance of at least 100 shares of Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a reverse split, the conversion ratio shall not be changed. However, in the event a forward split shall occur then the conversion ratio shall be modified to be increased by the same ratio as the forward split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated the Series B Preferred Stock in accordance with ASC 815 and has determined their conversion options were for equity and ASC 815 did not apply as of September 30, 2021. The Company has evaluated the Series B Preferred Stock in accordance with FASB ASC Subtopic 47020 and has determined that there is no beneficial conversion feature that must be accounted for as of September 30, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2021, there were <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares outstanding">8,000</span> shares of Series B Preferred outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Warrants - </b>On November 23, 2020, the Company issued a class A and a class B warrant to Coral Investment Partners, LP (“CIP”), with each warrant granting CIP the right to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__custom--WarrantClassAMember_pdd" title="Warrants outstanding"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__custom--WarrantClassBMember_pdd" title="Warrants outstanding">500,000</span></span> shares of common stock at a price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__custom--WarrantClassAMember_pdd" title="Warrant exercise price">2</span> for Class A or $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__custom--WarrantClassBMember_pdd" title="Warrant exercise price">5</span> for Class B. The warrants expire on <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__custom--WarrantClassAMember_zhjDLcCLfwT5" title="Warrant expiration date"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20201123__srt--CounterpartyNameAxis__custom--CoralInvestmentPartnersMember__us-gaap--StatementClassOfStockAxis__custom--WarrantClassBMember_zxBShTZhXOOj" title="Warrant expiration date">November 30, 2023</span></span>. The warrants also contain a cashless exercise provision and contained anti-dilution provisions. The warrants remain outstanding as of September 30, 2021. Subsequent to the quarter end, the Company was notified by the warrant holder that they intend to exercise its right to purchase shares of the Company under these warrants. SEE NOTE 10.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 28, 2021, the Company issued a warrant to a third party in exchange for professional services, granting the warrant holder the right to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210528__srt--CounterpartyNameAxis__custom--WarrantHolderMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_pdd" title="Warrants outstanding">500,000</span> shares of common stock at a price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210528__srt--CounterpartyNameAxis__custom--WarrantHolderMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_pdd" title="Warrant exercise price">1</span> per share, <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210528__srt--CounterpartyNameAxis__custom--WarrantHolder1Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_pdd" title="Warrants outstanding">500,000</span> shares at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210528__srt--CounterpartyNameAxis__custom--WarrantHolder1Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_pdd" title="Warrant exercise price">2</span> per share, and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210528__srt--CounterpartyNameAxis__custom--WarrantHolder2Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_pdd" title="Warrants outstanding">500,000</span> at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210528__srt--CounterpartyNameAxis__custom--WarrantHolder2Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_pdd" title="Warrant exercise price">5 </span>per share. The warrants expire on <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210528__srt--CounterpartyNameAxis__custom--WarrantHolderMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_zosHJ9vtcCVc" title="Warrant expiration date">June 1, 2026</span>. All warrants were outstanding on September 30, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30th, 2021, the Company issued a warrant to a third party in exchange for professional services, granting the warrant holder the right to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210730__srt--CounterpartyNameAxis__custom--WarrantHolderMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_zoO14UWS8j8k" title="Warrants outstanding">200,000</span> shares of common stock at a price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210730__srt--CounterpartyNameAxis__custom--WarrantHolderMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_zXHsrcGHnafk" title="Warrant exercise price">1</span> per share, <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210730__srt--CounterpartyNameAxis__custom--WarrantHolder1Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_zTeNju0aI5Oe" title="Warrants outstanding">100,000</span> shares at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210730__srt--CounterpartyNameAxis__custom--WarrantHolder1Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_z96YYD659Apc" title="Warrant exercise price">2</span> per share, and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210730__srt--CounterpartyNameAxis__custom--WarrantHolder2Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_zRObPtD34bb2" title="Warrants outstanding">100,000</span> at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210730__srt--CounterpartyNameAxis__custom--WarrantHolder2Member__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_z6hokzvDsuaj" title="Warrant exercise price">5</span> per share. The warrants expire on <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20210730__srt--CounterpartyNameAxis__custom--WarrantHolderMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_z1z43WmwsKNk" title="Warrant expiration date">July 26, 2026</span>. All warrants were outstanding on September 30, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 22, 2021, the Company issued a warrant in conjunction with the termination of the license right (see Note 3) with Purple Biotech, granting Purple Biotech the right to purchase 300,000 shares of common stock at $5 per share, subject to certain adjustments. During the three and nine months ending September 30, 2021, the Company recorded $1,897,585 as general and administrative expense in condensed consolidated statement of operations upon immediate vesting of the Warrant. The warrant was valued using the Black-Scholes option pricing model using the following assumptions: 1) exercise price of $5.00 per share, 2) fair value of $6.50 per share, 3) discount rate of 0.48%, 3) dividend rate of 0%, and 4) a term of 3 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 760000000 750000000 750000000 0.0001 0.0001 10000000 10000000 0.0001 0.0001 34750733 34750733 21952640 21952640 13064256 5952069 0 0 0 2000000 0.0001 8000 500000 500000 2 5 2023-11-30 2023-11-30 500000 1 500000 2 500000 5 2026-06-01 200000 1 100000 2 100000 5 2026-07-26 <p id="xdx_809_ecustom--AssetPurchaseAgreementTextBlock_z3pHNmwlnKe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 – <span id="xdx_82C_zyBbKD4wgOkc">ASSET PURCHASE AGREEMENT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 18, 2019, the Company entered into an Asset Purchase Agreement with ANI Pharmaceuticals, Inc. (ANI) for the sale of certain intellectual property and materials related to the research and development related to potential ANDA candidates. The Company recognized revenue of approximately $<span id="xdx_903_eus-gaap--Revenues_c20190101__20190618__us-gaap--TransactionTypeAxis__custom--AssetPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--AniPharmaceuticalsMember_pp0p0" title="Revenue recognized from assets sale">2,300,000</span> related to the Asset Purchase Agreement in the year ended December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the original purchase price, the Company is due an additional $2,000,000 with respect to the Product that is Vigabatrin 500mg tablets (tablets) as follows; (A) $250,000 within 30 days following the completion of all bioequivalence studies related to tablets, (B) $250,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $1,000,000 in a calendar year, (C) $500,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $5,000,000 in a calendar year, (D) $1,000,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $10,000,000 in a calendar year. As of nine months ended September 30, 2021 and 2020, and through this date, none of these milestones have occurred. Because collection of these milestone payments is not reasonably assured, we have not recorded any revenues in the accompanying financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, the Company is due an additional $1,750,000 with respect to the Product that is Vigabatrin 500mg powder for Oral Solution (powder) as follows; (A) $250,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $1,000,000 in a calendar year, (B) $500,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $5,000,000 in a calendar year, (C) $1,000,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $10,000,000 in a calendar year. As of nine months ended September 30, 2021 and 2020, and through this date, none of these milestones have occurred. Because collection of these milestone payments is not reasonably assured, we have not recorded any revenues in the accompanying financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 2300000 <p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_znW8xnxGYeW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 – <span id="xdx_82B_zf3DEZZmY679">COMMITMENTS AND CONTINGENCIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Leases </b>- The Company leases office space under an operating lease commencing December 1, 2017 through November 30, 2019 and a first lease extensions commending December 1, 2019 through May 31, 2020. The second lease extension extends the lease for twenty-four months, beginning on June 1, 2020 and ending on May 31, 2022. The monthly rent is $3,750. On January 1, 2019, the Company adopted ASC Topic 842, Leases, requiring this lease to be recorded as an asset and corresponding liability on its consolidated balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. During the nine months ended September 30, 2021 and 2020, rental expense totaled $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20210101__20210930_pp0p0" title="Operating lease expense">33,750</span> and $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20200101__20200930_pp0p0" title="Operating lease expense">32,250</span> respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future minimum rental payments required under the lease are as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zHwoOLuG1WP5" style="margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8B7_zqGnbgD4WHA3" style="display: none">Schedule of future minimum rental payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_496_20210930_zwj7o6mH9Soh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 33%">2021 (remaining 3 months)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">11,250</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Matters </b>– The company is currently not a defendant in any litigation or threatened litigation that could have a material effect on the company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Royalty Obligations - </b>In connection with the product licensing agreement discussed in Note 3, the Company owes a minimum royalty payment of $<span id="xdx_902_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_c20210930_pp0p0" title="Royalty payable">1,000,000</span> following the first year of product sales. A minimum royalty amount is also due in subsequent years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Royalty Advances </b>- In the nine months ended September 30, 2021 and 2020, the Company received royalty advances on future product sales of $<span id="xdx_90B_eus-gaap--ProceedsFromRoyaltiesReceived_c20210101__20210930_pp0p0" title="Proceeds from royalties">0</span> and $<span id="xdx_905_eus-gaap--ProceedsFromRoyaltiesReceived_c20200101__20200930_pp0p0" title="Proceeds from royalties">250,000</span>, respectively, from its pharmaceutical marketing partner. Interest is due on this advance and will continue to accrue at the rate of 10% until the payment is fully recouped from royalties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Minimum Payment Obligation – </b>In connection with a supply agreement with Coeptis’ drug product distributor related to Consensi, an amendment was entered into which (i) removes the requirement of a minimum payment obligation from such product distributor to Coeptis in regard to the sale of Consensi and (ii) clarifies that the upfront payment that was made from the product distributor to Coeptis may only be recouped by the product distributor through an offset against royalty payments that may otherwise become payable to Coeptis under the supply agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 33750 32250 <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zHwoOLuG1WP5" style="margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8B7_zqGnbgD4WHA3" style="display: none">Schedule of future minimum rental payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_496_20210930_zwj7o6mH9Soh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 33%">2021 (remaining 3 months)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">11,250</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 11250 18750 1000000 0 250000 <p id="xdx_80B_eus-gaap--CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_zEVyyxqTddcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 - <span id="xdx_821_zP00AfzyRXQk">401(k) PROFIT-SHARING PLAN</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company sponsors a qualified profit-sharing plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee elective deferrals but has no contribution requirements for the Company. During the nine months ended September 30, 2021 and 2020, <span id="xdx_904_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20210101__20210930_zvkRGFt4r7T8" title="Employer contribution"><span id="xdx_90F_eus-gaap--DefinedBenefitPlanContributionsByEmployer_pp0p0_do_c20200101__20200930_zeslw21UewUk" title="Employer contribution">no</span></span> employer contributions were made, and as of September 30, 2021 contributions to the plan will no longer be accepted as the plan is no longer active.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0 0 <p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zI8sa41mYpga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 – <span id="xdx_82B_zRNBYgupNZQe">INCOME TAXES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the nine months ended September 30, 2021 and 2020, respectively, <span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_do_c20210101__20210930_zTmleb2JjRj7" title="Income tax expense benefit"><span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_do_c20200101__20200930_z2lYXvSe33a7" title="Income tax expense benefit">no</span></span> income tax expense or benefit was recognized. The Company’s deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0 0 <p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_zhAHrhGvT4Cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 – <span><span><span id="xdx_823_zK1oEIbj93Gl">SUBSEQUENT EVENT</span></span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into an agreement with a Shareholder to surrender shares of Common Stock in exchange for the settlement of debt owed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2021, the Company was notified by the Class A and Class B warrant holder that it is exercising its right to purchase shares of the company under its warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
9 Months Ended
Sep. 30, 2021
Nov. 15, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 000-56194  
Entity Registrant Name Coeptis Therapeutics, Inc.  
Entity Central Index Key 0001819663  
Entity Tax Identification Number 84-3998117  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 105 Bradford Rd  
Entity Address, Address Line Two Suite 420  
Entity Address, City or Town Wexford  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 15090  
City Area Code (724)  
Local Phone Number 934-6467  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   36,441,999
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
CURRENT ASSETS    
Cash $ 2,809,861 $ 202,965
Accounts receivable 26,302 21,786
Inventories 0 0
TOTAL CURRENT ASSETS 2,836,164 224,751
PROPERTY AND EQUIPMENT    
Furniture and fixtures 25,237 25,237
Less: accumulated depreciation (10,944) (9,730)
Furniture and fixtures, net 14,293 15,507
OTHER ASSETS    
Co-development options 4,804,167 0
Right-of-use asset, net of accumulated amortization 28,352 58,225
Other assets 0 2,000
Total other assets 4,832,519 60,225
TOTAL ASSETS 7,682,976 300,484
CURRENT LIABILITIES    
Accounts payable 1,281,314 1,623,840
Accrued expenses 153,811 732,146
Notes payable, current portion 3,999,595 1,277,500
Notes payable, related parties, current portion 0 604,000
Right of use liability, current portion 10,758 41,618
Deferred revenue 0 1,000,000
TOTAL CURRENT LIABILITIES 5,445,478 5,279,104
LONG TERM LIABILITIES    
Note payable 1,650,000 150,000
Right of use liability, non-current portion 14,723 14,723
TOTAL LONG TERM LIABILITIES 1,664,723 164,723
TOTAL LIABILITIES 7,110,201 5,443,827
STOCKHOLDERS' EQUITY (DEFICIT)    
Series B Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, 8,000 and -0- shares issued and outstanding, respectively 1 0
Common stock, $0.0001 par value, 750,000,000 shares authorized, 34,750,733 and 25,178,840 shares issued and outstanding, respectively 3,317 2,519
Additional paid-in capital 23,902,974 8,954,985
Common stock subscribed 1,377,000 0
Accumulated deficit (24,710,518) (14,100,846)
TOTAL STOCKHOLDERS' EQUITY 572,774 (5,143,342)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 7,682,976 $ 300,484
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 8,000 0
Preferred stock, shares outstanding 8,000 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 750,000,000 750,000,000
Common stock, shares issued 34,750,733 25,178,840
Common stock, shares outstanding 34,750,733 25,178,840
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
SALES        
Total sales $ 0 $ 9,888 $ 75,000 $ 30,761
Cost of goods, including inventory obsolescence 0 1,492 0 3,361
Gross profit 0 8,396 75,000 27,400
COST OF OPERATIONS        
Research and development 0 0 0 3,543
General and administrative expenses 6,759,339 1,433,621 11,077,747 2,437,725
Selling and marketing 0 0 2,918 0
Interest expense 188,559 183,871 266,382 262,826
Total operating expenses 6,947,898 1,617,492 11,347,048 2,704,094
LOSS FROM OPERATIONS (6,947,898) (1,609,097) (11,272,048) (2,676,694)
OTHER INCOME (EXPENSE)        
Royalties and licensing fees 3,543 (211,550) (413,124) (1,711,550)
Other Income 0 0 77,500 0
Gain (Loss) on write down of assets (2,000) 0 (2,000) 0
TOTAL OTHER INCOME (EXPENSE) 1,001,543 (211,550) 662,376 (1,711,550)
LOSS BEFORE INCOME TAXES (5,946,356) (1,820,647) (10,609,672) (4,388,244)
PROVISION FOR INCOME TAXES (BENEFIT) 0 0 0 0
NET LOSS $ (5,946,356) $ (1,820,647) $ (10,609,672) $ (4,388,244)
LOSS PER SHARE        
Loss per share, basic and fully diluted $ (0.17) $ (0.09) $ (0.34) $ (0.23)
Weighted average number of common shares outstanding 34,060,556 20,164,597 31,054,813 18,756,999
Consulting Services [Member]        
SALES        
Total sales $ 0 $ 9,888 $ 75,000 $ 30,761
Other Sales [Member]        
SALES        
Total sales $ 0 $ 0 $ 0 $ 0
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
Preferred Stock Series B [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Common Stock Subscribed [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 1,620 $ 5,464,465 $ 100,000 $ (4,944,559) $ 621,526
Balance at beginning, shares at Dec. 31, 2019 16,196,000        
Retroactive application of recapitalization $ 1,588,800 $ (297,949) (297,949)
Retroactive application of recapitalization, shares          
Adjusted balance, beginning of period $ 1,620 5,166,516 100,000 (4,944,559) 323,577
Adjusted balance, beginning of period, Shares   17,784,800        
Shares issued for cash $ 20 99,980 (100,000)
Shares issued for cash, shares   200,000        
Net income (loss) (1,896,399) (1,896,399)
Ending balance, value at Mar. 31, 2020 $ 1,640 5,266,496 (6,840,958) (1,572,822)
Balance at ending, shares at Mar. 31, 2020 17,984,800        
Beginning balance, value at Dec. 31, 2019 $ 1,620 5,464,465 100,000 (4,944,559) 621,526
Balance at beginning, shares at Dec. 31, 2019 16,196,000        
[custom:WarrantsIssuedForServices]           0
Ending balance, value at Sep. 30, 2020 $ 2,037 6,250,019 100,000 (9,346,859) (2,994,803)
Balance at ending, shares at Sep. 30, 2020 21,952,640        
Beginning balance, value at Mar. 31, 2020 $ 1,640 5,266,496 (6,840,958) (1,572,822)
Balance at beginning, shares at Mar. 31, 2020 17,984,800        
Shares issued for cash
Shares issued for services $ 67 333,853 333,920
Shares issued for services, shares   667,840        
Net income (loss) (685,254) (685,254)
Ending balance, value at Jun. 30, 2020 $ 1,707 5,600,349 (7,526,212) (1,924,156)
Balance at ending, shares at Jun. 30, 2020 18,652,640        
Shares issued for cash $ 330 649,670 100,000 750,000
Shares issued for cash, shares   3,300,000        
Shares issued for services
Net income (loss) (1,820,647) (1,820,647)
Ending balance, value at Sep. 30, 2020 $ 2,037 6,250,019 100,000 (9,346,859) (2,994,803)
Balance at ending, shares at Sep. 30, 2020 21,952,640        
Beginning balance, value at Dec. 31, 2020 $ 2,519 8,954,985 (14,100,846) (5,143,342)
Balance at beginning, shares at Dec. 31, 2020 25,178,840        
Retroactive application of recapitalization $ 1 (298,062) (298,061)
Retroactive application of recapitalization, shares 8,000 1,589,400        
Shares issued for cash $ 244 2,436,256 471,000 2,907,500
Shares issued for cash, shares   2,436,500        
Shares issued for services $ 77 769,923 770,000
Shares issued for services, shares   770,000        
Net income (loss) (1,950,081) (1,950,081)
Ending balance, value at Mar. 31, 2021 $ 1 $ 2,839 11,863,102 471,000 (16,050,927) (3,713,985)
Balance at ending, shares at Mar. 31, 2021 8,000 29,974,740        
Beginning balance, value at Dec. 31, 2020 $ 2,519 8,954,985 (14,100,846) (5,143,342)
Balance at beginning, shares at Dec. 31, 2020 25,178,840        
[custom:WarrantsIssuedForServices]           2,978,771
Ending balance, value at Sep. 30, 2021 $ 1 $ 3,317 23,902,975 1,377,000 (24,710,518) 572,774
Balance at ending, shares at Sep. 30, 2021 8,000 34,750,733        
Beginning balance, value at Mar. 31, 2021 $ 1 $ 2,839 11,863,102 471,000 (16,050,927) (3,713,985)
Balance at beginning, shares at Mar. 31, 2021 8,000 29,974,740        
Shares issued for cash $ 128 1,922,368 (388,500) 1,533,996
Shares issued for cash, shares   1,281,664        
Shares issued for services $ 69 1,034,931 1,035,000
Shares issued for services, shares   690,000        
Warrants issued for services 676,892 676,892
Net income (loss) (2,713,235) (2,713,235)
Shares issued through conversion of debt $ 69 1,040,931 1,041,000
Shares issued through conversion of debt, Shares   694,000        
Ending balance, value at Jun. 30, 2021 $ 1 $ 3,106 16,538,223 82,500 (18,764,162) (2,140,332)
Balance at ending, shares at Jun. 30, 2021 8,000 32,640,404        
Shares issued for cash $ 171 2,557,828 1,294,500 3,852,499
Shares issued for cash, shares   1,705,329        
Shares issued for services $ 41 607,460 607,500
Shares issued for services, shares   405,000        
Warrants issued for services 2,301,879 2,301,879
Net income (loss) (5,946,356) (5,946,356)
Stock based compensation 1,897,585 1,897,585
Ending balance, value at Sep. 30, 2021 $ 1 $ 3,317 $ 23,902,975 $ 1,377,000 $ (24,710,518) $ 572,774
Balance at ending, shares at Sep. 30, 2021 8,000 34,750,733        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
OPERATING ACTIVITIES    
Net income (loss) $ (10,609,672) $ (4,388,244)
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:    
Depreciation and amortization 1,214 1,444
Forgiveness of debt (77,500) 0
Interest paid 0 0
Shares issued for non-employee services 2,412,500 333,920
Warrants issued for services 2,978,771 0
Stock based compensation 1,897,585 0
Shares issued for conversion of debt 1,041,000 0
Increase (decrease) in:    
Accounts receivable (4,516) (14,907)
Inventories 0 (1,014,659)
Right of use asset/liability (988) 1,945
Accounts payable (340,621) 1,916,183
Accrued expenses (578,335) 112,806
Deferred revenue (1,000,000) 500,000
NET CASH USED IN OPERATING ACTIVITIES (4,280,561) (2,551,512)
INVESTING ACTIVITIES    
Purchase of license right (4,804,167) 0
Purchase of property and equipment 0 0
NET CASH USED IN INVESTING ACTIVITIES (4,804,167) 0
FINANCING ACTIVITIES    
Proceeds from notes payable 4,827,595 1,227,500
Proceeds from notes payable, related parties 0 604,000
Repayment of notes payable (527,905) 0
Repayment of notes payable, related parties (604,000) 0
Shares from merger transaction (298,061) 0
Shares issued for cash 6,916,994 650,000
Cash received for stock subscription 1,377,000 100,000
NET CASH PROVIDED BY FINANCING ACTIVITIES 11,691,623 2,581,500
NET INCREASE IN CASH 2,606,897 29,988
CASH AT BEGINNING OF PERIOD 202,965 440,088
CASH AT END OF PERIOD 2,809,861 470,076
SUPPLEMENTAL DISCLOSURES    
Taxes paid (refunded) $ 0 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Nature of Business – Coeptis Pharmaceuticals, LLC (LLC) was formed in July 12, 2017 as a Pennsylvania multi-member limited liability company. On December 1, 2018, the members of LLC contributed their interest to a newly formed corporation, Coeptis Pharmaceuticals, Inc (“Coeptis”). As of December 1, 2018, the LLC became a disregarded single-member limited liability company which is wholly owned by the newly formed corporation. On February 12, 2021, Vinings Holdings, Inc., a Delaware corporation (“Vinings”), merged (the “Merger”) with and into Coeptis Pharmaceuticals, Inc. On July 12, 2021, the company has legally changed its name from Vinings Holdings, Inc. to Coeptis Therapeutics, Inc. Coeptis was the surviving corporation of that Merger. As a result of the Merger, Vinings acquired the business of Coeptis and will continue the existing business operations of Coeptis as a wholly owned subsidiary. The Merger was treated as a recapitalization of the Company for financial accounting purposes. The historical financial statements of Vinings before the Merger were replaced with the historical financial statements of Coeptis before the Merger in all future filings with the Securities and Exchange Commission (the “SEC”).

 

The Company is located in Wexford, PA, and engages primarily in the acquisition, development, and commercialization of pharmaceutical products.

 

Basis of Presentation - The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of September 30, 2021, along with its results of operations for the three and nine month periods ended September 30, 2021 and 2020 and cash flows for the nine-month periods ended September 30, 2021 and 2020. Interim financial statements are prepared on a basis consistent with the Company’s annual financial statements and should be read in conjunction with our Annual Report on Form 10-KT for the fiscal year ended December 31, 2020. Results of operations for the nine-month period ended September 30, 2021, are not necessarily indicative of the operating results that may be expected for the full year ending December 31, 2021.

 

As a result of the Merger, the financial statements included in this report reflect (1) the historical operating results of Coeptis prior to the Merger; (2) the combined results of the Company and Coeptis following the closing of the Merger; (3) the assets and liabilities of Coeptis at their historical cost; and (4) the Company’s equity structure for all periods presented.

 

Risks and Uncertainties - In late 2019, an outbreak of a novel strain of the Coronavirus 2019 Disease (COVID-19) was identified and infections have been found in a number of countries around the world, including the United States. COVID-19 and its impact on trade including customer demand, travel, employee productivity, supply chain, and other economic activities has had, and may continue to have, a potentially significant effect on financial markets and business activity. The extent of the impact of COVID-19 on the Company’s operational and financial performance is currently uncertain and cannot be predicted.

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company’s significant accounting policies are described in Note 2 “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-KT filed with the U.S. Securities and Exchange Commission (“SEC”) on May 11, 2021. There have been no material changes to the significant accounting policies during the period ended September 30, 2021, except for items mentioned below.

 

Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Coeptis Therapeutics Inc., Coeptis Pharmaceuticals, Inc. and its wholly-owned subsidiary, Coeptis Pharmaceuticals, LLC. All material intercompany accounts, balances and transactions have been eliminated.

 

Use of Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Accounting for non-employee share-based paymentsThe Company may from time to time issue share based compensation to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to equity instruments for the settlement of services provided by non-employees is recorded on the statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. Warrants that provide the option to purchase common stock are accounted for in accordance with ASC 718-10-35-1D, where the total cost of the compensation is based on the number of instruments for which a service has been rendered, and recognized over the period that the service is performed. To determine the amount of compensation cost to be recognized in each period, the Company shall recognize the effect of forfeitures in compensation cost when they occur. Previously recognized compensation cost shall be reversed in the period that the award is forfeited.

 

Adoption of New Accounting Pronouncements – In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.

 

During the nine months ended September 30, 2021, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
LICENSE RIGHT
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
LICENSE RIGHT

NOTE 3 – LICENSE RIGHT

 

In 2019, the Company entered into an agreement with a foreign entity to market, distribute, and sell the Consensi product (Product) on an exclusive basis within the United States and Puerto Rico. Upon execution of the Agreement the Company paid $1,000,000 to the foreign entity. Milestone payments were due as follows; (1) $1,500,000 upon completion of the CMC Plan as reimbursements of costs incurred by the foreign entity, (2) $1,000,000 was due upon first commercial sale of the Product which occurred in June 2020. Milestones were not met during nine months ended September 30, 2021 and 2020.

 

During the fourth quarter of 2020, the Company determined that there was a reduction of the useful life of the asset, resulting in a full impairment of the asset. The carrying value of the license right at September 30, 2021 and December 31, 2020 was $0. Amortization expenses total $0 and $0 for the nine months ended September 30, 2021 and 2020, respectively.

 

In September of 2021, the Company executed a license termination agreement with the foreign entity to cease all efforts for sales and promotion of the product in the United States and Puerto Rico. The termination included issuance of $1,500,000 of convertible debt due in 2023 to satisfy amounts owed for the license, issue of warrants (See NOTE 5) and transfer of inventory ownership back to the foreign entity. In conjunction with this termination, the Company also terminated its marketing agreement with a third party for the Product’s sales and promotion.

 

On May 6, 2021, the Company made initial payments under two definitive agreements. The two definitive option purchase agreements are with VyGen-Bio, Inc. (“Vy-Gen”), pursuant to which the Company has the exclusive option to acquire co-development rights with respect to two Vy-Gen product candidates. The Company paid a total of $750,000 to acquire the two exclusive options. On August 15, 2021, the Company entered into amendments to each of the two definitive option purchase agreements, in connection with such amendments the Company delivered promissory notes aggregating $3,250,000 with maturity dates of December 31, 2021. In connection with the two amendments the Company plans to pay a cash payment of $1,000,000, and thereby the Company will be deemed to have exercised the two options. In the event that the promissory notes are timely paid by December 31, 2021, the Company will maintain its 50% ownership interest in the two Vy-Gen product candidates, and if the promissory notes are not timely paid by December 31, 2021 the Company’s ownership interest in such assets will automatically be reduced to 20%, in which case the two promissory notes will be automatically cancelled and will no longer be due or payable.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
LONG-TERM DEBT
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
LONG-TERM DEBT

NOTE 4 – LONG-TERM DEBT

 

The Company entered into a note payable agreement with an unrelated company with a conversion option. The principal amount of $200,000, which is unsecured, together with interest at 9% was due June 15, 2020. In lieu of cash repayment, the outstanding principal amount of the note, plus all accrued unpaid interest may be converted at the option of the party, in whole or in part, into shares of Common Stock. As of the December 31, 2020, the note had a balance of $200,000. The note and accrued interest were paid in full in the first quarter of 2021.

 

In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $500,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. The balance of the note is $500,000 as of September 30, 2021 and December 31, 2020. This debt is currently in default.

 

In January 2020, the Company entered into a Senior Secured Note agreement with a related party stockholder. The principal amount of $250,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. This debt was converted to equity in June 2021. The balance of the note was $0 and $250,000 as of September 30, 2021 and December 31, 2020, respectively.

 

In January 2020, the Company entered into another Senior Secured Note agreement with a stockholder. The principal amount of $250,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. This debt was converted to equity in June 2021. The balance of the note is $0 and $250,000 as of September 30, 2021 and December 31, 2020, respectively.

 

In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $333,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. This debt was converted to equity in June 2021. The balance of the note was $0 and $333,000 as of September 30, 2021 and December 31, 2020, respectively.

 

In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $167,000, which is secured by a security agreement, together with interest at 8%, plus additional 2% in the event of default, was due February 8, 2021. The balance of the note is $167,000 as of September 30, 2021 and December 31, 2020. This debt is currently in default.

 

In September 2020, the Company entered a non-interest bearing, unsecured note agreement with two shareholders for $104,000 with an unspecified due date. The note was converted to equity in June 2021. The balance was $0 and $104,000 as of September 30, 2021 and December 31, 2020.

 

In September 2021, as part of a termination of license agreement with Purple BioTech, the Company issued a convertible note in the principle amount of $1,500,000 that is payable on or before February 2023, bearing interest of 5% per annum and convertible in whole or in part at any time by Purple BioTech into shares of Coeptis’ common stock. The conversion price is $5 per share of common stock, subject to certain adjustments under such terms and conditions as agreed between the parties. Coeptis may prepay the principal amount of the Note plus accrued and unpaid interest at any time, prior to the Maturity Date. Inventory, which has been fully written-off on the Company’s balance sheet, will be transferred back to Purple at Purple’s cost.

 

Interest accrued on the related party notes at September 30, 2021 and December 31,2020 was $0 and $40,000, respectively.

 

Loans under the CARES Act -- On May 6, 2020, the Company received loan proceeds in the amount of approximately $77,500 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. In February 2021, an additional $77,595 was received by the Company under the second round of PPP (“PPP2”). The Company has used the proceeds for purposes consistent with its intended use. The initial loan was forgiven in the amount of $77,500 in principal and $893.40 in interest on June 25, 2021. The Company applied for PPP2 loan forgiveness in September 2021 and received full forgiveness in October 2021. As of September 30, 2021, and December 31, 2020, the balance of the notes totaled $77,595 and $77,500, respectively.

 

On July 8, 2020 the Company received a loan of $150,000 from the from the United States Small Business Administration (the “SBA”) under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Proceeds are intended to be used for working capital purposes. Interest on the EIDL Loan accrues at the rate of 3.75% per annum and installment payments, including principal and interest, are due monthly beginning July 2022 in the amount of $731. The balance of principal and interest is payable thirty years from the date of the promissory note. The balance of the loan is $150,000, as of September 30, 2021 and December 31, 2020.

 

Maturities of long-term debt for the quarter ended September 30, 2021 are as follows: 

      
2022    
2023   1,502,001 
2024   5,279 
2025   8,682 
Thereafter   134,038 
Total long-term debt  $1,650,000 

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
CAPITAL STRUCTURE
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
CAPITAL STRUCTURE

NOTE 5 – CAPITAL STRUCTURE

 

The total number of shares of stock which the corporation shall have authority to issue is 760,000,000 shares, of which 750,000,000 shares of $0.0001 par value shall be designated as Common Stock and 10,000,000 shares of $0.0001 shall be designated as Preferred Stock. The Preferred Stock authorized by these Articles of Incorporation may be issued in one or more series. The Board of Directors of the Corporation is authorized to determine or alter the rights, preferences, privileges, and restrictions granted or imposed upon any wholly unissued series of Preferred Stock, and within the limitations or restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any such series subsequent to the issue of shares of that series, to determine the designation and par value of any series and to fix the numbers of shares of any series.

 

Common Stock - As of September 30, 2021 the Company had 34,750,733 shares of its common stock issued and outstanding, and on September 30, 2020 the Company had 21,952,640 shares of its common stock issued and outstanding. All references to the common shares outstanding have been retroactively adjusted to reflect the stock splits unless stated otherwise.

 

In 2021 and 2020, the Company raised capital by issuance of common stock above the stated par value. The contributed capital recognized as additional paid in capital during the nine months ended September 30, 2021 and 2020 was $13,064,256 and $5,952,069 respectively. During the nine months ended September 30, 2021 and 2020, there were $0 in capital distributions.

 

Series A Preferred Stock - As of April 30, 2019, the Series A Preferred Stock had been canceled, and no shares remain outstanding. The rights and privileges of future issuances of the Series A Preferred stock will be determined at such time if and when they are issued. As of September 30, 2021, there were 0 shares of Series A Preferred outstanding.

 

Series B Convertible Preferred Stock - The Company designated 2,000,000 shares of Series B Convertible Preferred Stock with a par value of $0.0001 per share. Initially, there will be no dividends due or payable on the Series B Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.

 

All shares of the Series B Preferred Stock shall rank (i) senior to the Corporation’s Common Stock and any other class or series of capital stock of the Corporation hereafter created, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series B Preferred Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series B Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.

 

The Series B Preferred shall have no liquidation preference over any other class of stock.

 

Each holder of outstanding shares of Series B Preferred Stock shall be entitled to the number of votes equal to equal to one thousand (1,000) Common Shares. Except as provided by law, or by the provisions establishing any other series of Preferred Stock, holders of Series B Preferred Stock and of any other outstanding series of Preferred Stock shall vote together with the holders of Common Stock as a single class.

 

Each holder of shares of Series B Preferred Stock may, at any time and from time to time, convert (an “Optional Conversion”) each of its shares of Series B Preferred Stock into a 1,000 of fully paid and nonassessable shares of Common Stock; provided, however, that any Optional Conversion must involve the issuance of at least 100 shares of Common Stock.

 

In the event of a reverse split, the conversion ratio shall not be changed. However, in the event a forward split shall occur then the conversion ratio shall be modified to be increased by the same ratio as the forward split.

 

The Company has evaluated the Series B Preferred Stock in accordance with ASC 815 and has determined their conversion options were for equity and ASC 815 did not apply as of September 30, 2021. The Company has evaluated the Series B Preferred Stock in accordance with FASB ASC Subtopic 47020 and has determined that there is no beneficial conversion feature that must be accounted for as of September 30, 2021.

 

As of September 30, 2021, there were 8,000 shares of Series B Preferred outstanding.

 

Common Stock Warrants - On November 23, 2020, the Company issued a class A and a class B warrant to Coral Investment Partners, LP (“CIP”), with each warrant granting CIP the right to purchase 500,000 shares of common stock at a price of $2 for Class A or $5 for Class B. The warrants expire on November 30, 2023. The warrants also contain a cashless exercise provision and contained anti-dilution provisions. The warrants remain outstanding as of September 30, 2021. Subsequent to the quarter end, the Company was notified by the warrant holder that they intend to exercise its right to purchase shares of the Company under these warrants. SEE NOTE 10.

 

On May 28, 2021, the Company issued a warrant to a third party in exchange for professional services, granting the warrant holder the right to purchase 500,000 shares of common stock at a price of $1 per share, 500,000 shares at $2 per share, and 500,000 at $5 per share. The warrants expire on June 1, 2026. All warrants were outstanding on September 30, 2021.

 

On July 30th, 2021, the Company issued a warrant to a third party in exchange for professional services, granting the warrant holder the right to purchase 200,000 shares of common stock at a price of $1 per share, 100,000 shares at $2 per share, and 100,000 at $5 per share. The warrants expire on July 26, 2026. All warrants were outstanding on September 30, 2021.

 

On September 22, 2021, the Company issued a warrant in conjunction with the termination of the license right (see Note 3) with Purple Biotech, granting Purple Biotech the right to purchase 300,000 shares of common stock at $5 per share, subject to certain adjustments. During the three and nine months ending September 30, 2021, the Company recorded $1,897,585 as general and administrative expense in condensed consolidated statement of operations upon immediate vesting of the Warrant. The warrant was valued using the Black-Scholes option pricing model using the following assumptions: 1) exercise price of $5.00 per share, 2) fair value of $6.50 per share, 3) discount rate of 0.48%, 3) dividend rate of 0%, and 4) a term of 3 years.

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
ASSET PURCHASE AGREEMENT
9 Months Ended
Sep. 30, 2021
Asset Purchase Agreement  
ASSET PURCHASE AGREEMENT

NOTE 6 – ASSET PURCHASE AGREEMENT

 

On June 18, 2019, the Company entered into an Asset Purchase Agreement with ANI Pharmaceuticals, Inc. (ANI) for the sale of certain intellectual property and materials related to the research and development related to potential ANDA candidates. The Company recognized revenue of approximately $2,300,000 related to the Asset Purchase Agreement in the year ended December 31, 2019.

 

In addition to the original purchase price, the Company is due an additional $2,000,000 with respect to the Product that is Vigabatrin 500mg tablets (tablets) as follows; (A) $250,000 within 30 days following the completion of all bioequivalence studies related to tablets, (B) $250,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $1,000,000 in a calendar year, (C) $500,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $5,000,000 in a calendar year, (D) $1,000,000 within 45 days of the first date on which annual gross profit from the sale of tablets reaches $10,000,000 in a calendar year. As of nine months ended September 30, 2021 and 2020, and through this date, none of these milestones have occurred. Because collection of these milestone payments is not reasonably assured, we have not recorded any revenues in the accompanying financial statements.

 

Also, the Company is due an additional $1,750,000 with respect to the Product that is Vigabatrin 500mg powder for Oral Solution (powder) as follows; (A) $250,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $1,000,000 in a calendar year, (B) $500,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $5,000,000 in a calendar year, (C) $1,000,000 within 45 days of the first date on which annual gross profit from the sale of powder reaches $10,000,000 in a calendar year. As of nine months ended September 30, 2021 and 2020, and through this date, none of these milestones have occurred. Because collection of these milestone payments is not reasonably assured, we have not recorded any revenues in the accompanying financial statements.

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 7 – COMMITMENTS AND CONTINGENCIES

 

Leases - The Company leases office space under an operating lease commencing December 1, 2017 through November 30, 2019 and a first lease extensions commending December 1, 2019 through May 31, 2020. The second lease extension extends the lease for twenty-four months, beginning on June 1, 2020 and ending on May 31, 2022. The monthly rent is $3,750. On January 1, 2019, the Company adopted ASC Topic 842, Leases, requiring this lease to be recorded as an asset and corresponding liability on its consolidated balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. During the nine months ended September 30, 2021 and 2020, rental expense totaled $33,750 and $32,250 respectively.

 

Future minimum rental payments required under the lease are as follows: 

     
2021 (remaining 3 months)  $11,250 
2022   18,750 

 

Legal Matters – The company is currently not a defendant in any litigation or threatened litigation that could have a material effect on the company’s financial statements.

 

Royalty Obligations - In connection with the product licensing agreement discussed in Note 3, the Company owes a minimum royalty payment of $1,000,000 following the first year of product sales. A minimum royalty amount is also due in subsequent years.

 

Royalty Advances - In the nine months ended September 30, 2021 and 2020, the Company received royalty advances on future product sales of $0 and $250,000, respectively, from its pharmaceutical marketing partner. Interest is due on this advance and will continue to accrue at the rate of 10% until the payment is fully recouped from royalties.

 

Minimum Payment Obligation – In connection with a supply agreement with Coeptis’ drug product distributor related to Consensi, an amendment was entered into which (i) removes the requirement of a minimum payment obligation from such product distributor to Coeptis in regard to the sale of Consensi and (ii) clarifies that the upfront payment that was made from the product distributor to Coeptis may only be recouped by the product distributor through an offset against royalty payments that may otherwise become payable to Coeptis under the supply agreement.

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
401(k) PROFIT-SHARING PLAN
9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
401(k) PROFIT-SHARING PLAN

NOTE 8 - 401(k) PROFIT-SHARING PLAN

 

The Company sponsors a qualified profit-sharing plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee elective deferrals but has no contribution requirements for the Company. During the nine months ended September 30, 2021 and 2020, no employer contributions were made, and as of September 30, 2021 contributions to the plan will no longer be accepted as the plan is no longer active.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES
9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 9 – INCOME TAXES

 

For the nine months ended September 30, 2021 and 2020, respectively, no income tax expense or benefit was recognized. The Company’s deferred tax assets are comprised primarily of net operating loss carryforwards. The Company maintains a full valuation allowance on its deferred tax assets since it has not yet achieved sustained profitable operations. As a result, the Company has not recorded any income tax benefit since its inception.

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENT
9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENT

NOTE 10 – SUBSEQUENT EVENT

 

On October 1, 2021, the Company entered into an agreement with a Shareholder to surrender shares of Common Stock in exchange for the settlement of debt owed.

 

On October 20, 2021, the Company was notified by the Class A and Class B warrant holder that it is exercising its right to purchase shares of the company under its warrants.

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements include the accounts of Coeptis Therapeutics Inc., Coeptis Pharmaceuticals, Inc. and its wholly-owned subsidiary, Coeptis Pharmaceuticals, LLC. All material intercompany accounts, balances and transactions have been eliminated.

 

Use of Estimates

Use of Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Accounting for non-employee share-based payments

Accounting for non-employee share-based paymentsThe Company may from time to time issue share based compensation to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to equity instruments for the settlement of services provided by non-employees is recorded on the statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. Warrants that provide the option to purchase common stock are accounted for in accordance with ASC 718-10-35-1D, where the total cost of the compensation is based on the number of instruments for which a service has been rendered, and recognized over the period that the service is performed. To determine the amount of compensation cost to be recognized in each period, the Company shall recognize the effect of forfeitures in compensation cost when they occur. Previously recognized compensation cost shall be reversed in the period that the award is forfeited.

 

Adoption of New Accounting Pronouncements

Adoption of New Accounting Pronouncements – In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard, effective January 1, 2021, did not have a material impact on these financial statements.

 

During the nine months ended September 30, 2021, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
LONG-TERM DEBT (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
LONG-TERM DEBT
      
2022    
2023   1,502,001 
2024   5,279 
2025   8,682 
Thereafter   134,038 
Total long-term debt  $1,650,000 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Tables)
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of future minimum rental payments
     
2021 (remaining 3 months)  $11,250 
2022   18,750 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
LICENSE RIGHT (Details Narrative) - USD ($)
4 Months Ended 9 Months Ended 10 Months Ended
May 06, 2021
Sep. 30, 2021
Sep. 30, 2020
Aug. 15, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]          
License right   $ 4,804,167     $ 0
Amortization expense   0 $ 0    
Issuance of convertible debt   1,500,000      
Payments to Acquire Intangible Assets   4,804,167 $ (0)    
VyGen-Bio [Member]          
Finite-Lived Intangible Assets [Line Items]          
Notes Issued       $ 3,250,000  
Debt Instrument, Maturity Date       Dec. 31, 2021  
Consensi License Right [Member]          
Finite-Lived Intangible Assets [Line Items]          
License right   $ 0     $ 0
Vy Gen Options [Member]          
Finite-Lived Intangible Assets [Line Items]          
Payments to Acquire Intangible Assets $ 750,000        
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
LONG-TERM DEBT (Details)
Sep. 30, 2021
USD ($)
Debt Disclosure [Abstract]  
2022 $ 0
2023 1,502,001
2024 5,279
2025 8,682
Thereafter 134,038
Total long-term debt $ 1,650,000
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
LONG-TERM DEBT (Details Narrative) - USD ($)
2 Months Ended 4 Months Ended 6 Months Ended 9 Months Ended
Feb. 28, 2021
May 06, 2020
Jul. 08, 2020
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]          
Accrued interest       $ 0 $ 40,000
Debt Instrument, Decrease, Forgiveness       $ 77,500  
License Agreement [Member] | Purple Bio Tech [Member]          
Debt Instrument [Line Items]          
Debt Instrument, Interest Rate During Period       5.00%  
Debt Instrument, Convertible, Conversion Price       $ 5  
Note Payable [Member]          
Debt Instrument [Line Items]          
Principal amount       $ 200,000  
Debt stated interest rate       9.00%  
Debt maturity date       Jun. 15, 2020  
Note Payable 1 [Member]          
Debt Instrument [Line Items]          
Note payable         200,000
Note Payable 2 [Member]          
Debt Instrument [Line Items]          
Principal amount       $ 500,000  
Debt stated interest rate       8.00%  
Debt maturity date       Feb. 08, 2021  
Note payable       $ 500,000 500,000
Debt interest rate increase if in default       2.00%  
Note Payable 3 [Member]          
Debt Instrument [Line Items]          
Principal amount       $ 250,000  
Debt stated interest rate       8.00%  
Debt maturity date       Feb. 08, 2021  
Note payable       $ 0 250,000
Debt interest rate increase if in default       2.00%  
Note Payable 4 [Member]          
Debt Instrument [Line Items]          
Principal amount       $ 250,000  
Debt stated interest rate       8.00%  
Debt maturity date       Feb. 08, 2021  
Note payable       $ 0 250,000
Debt interest rate increase if in default       2.00%  
Note Payable 5 [Member]          
Debt Instrument [Line Items]          
Principal amount       $ 333,000  
Debt stated interest rate       8.00%  
Debt maturity date       Feb. 08, 2021  
Note payable       $ 0 333,000
Debt interest rate increase if in default       2.00%  
Note Payable 6 [Member]          
Debt Instrument [Line Items]          
Principal amount       $ 167,000  
Debt stated interest rate       8.00%  
Debt maturity date       Feb. 08, 2021  
Note payable       $ 167,000 167,000
Debt interest rate increase if in default       2.00%  
Note Payable 7 [Member]          
Debt Instrument [Line Items]          
Principal amount       $ 104,000  
Note payable       0 104,000
PPP Loan [Member]          
Debt Instrument [Line Items]          
Note payable       77,595 77,500
Proceeds from loan $ 77,595 $ 77,500      
EIDL Loan [Member]          
Debt Instrument [Line Items]          
Debt stated interest rate     3.75%    
Note payable       $ 150,000 $ 150,000
Proceeds from loan     $ 150,000    
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
CAPITAL STRUCTURE (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jul. 30, 2021
May 28, 2021
Dec. 31, 2020
Nov. 23, 2020
Class of Stock [Line Items]            
Number of share issued 760,000,000          
Common stock, shares authorized 750,000,000       750,000,000  
Common stock, par value $ 0.0001       $ 0.0001  
Preferred stock, shares authorized 10,000,000       10,000,000  
Preferred stock, par value $ 0.0001       $ 0.0001  
Common stock, shares issued 34,750,733       25,178,840  
Common stock, shares outstanding 34,750,733       25,178,840  
Additional paid in capital $ 13,064,256 $ 5,952,069        
Capital distributions $ 0 $ 0        
Preferred stock, shares outstanding 8,000       0  
Common Stock [Member]            
Class of Stock [Line Items]            
Common stock, shares issued 34,750,733 21,952,640        
Common stock, shares outstanding 34,750,733 21,952,640        
Series A Preferred Stock [Member]            
Class of Stock [Line Items]            
Preferred stock, shares outstanding 0          
Series B Convertible Preferred Stock [Member]            
Class of Stock [Line Items]            
Preferred stock, shares authorized 2,000,000          
Preferred stock, par value $ 0.0001          
Series B Preferred Stock [Member]            
Class of Stock [Line Items]            
Preferred stock, shares outstanding 8,000          
Warrant Class A [Member] | Coral Investment Partners [Member]            
Class of Stock [Line Items]            
Warrants outstanding           500,000
Warrant exercise price           $ 2
Warrant expiration date           Nov. 30, 2023
Warrant Class B [Member] | Coral Investment Partners [Member]            
Class of Stock [Line Items]            
Warrants outstanding           500,000
Warrant exercise price           $ 5
Warrant expiration date           Nov. 30, 2023
Common Stock Warrants [Member] | Warrant Holder [Member]            
Class of Stock [Line Items]            
Warrants outstanding     200,000 500,000    
Warrant exercise price     $ 1 $ 1    
Warrant expiration date     Jul. 26, 2026 Jun. 01, 2026    
Common Stock Warrants [Member] | Warrant Holder 1 [Member]            
Class of Stock [Line Items]            
Warrants outstanding     100,000 500,000    
Warrant exercise price     $ 2 $ 2    
Common Stock Warrants [Member] | Warrant Holder 2 [Member]            
Class of Stock [Line Items]            
Warrants outstanding     100,000 500,000    
Warrant exercise price     $ 5 $ 5    
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
ASSET PURCHASE AGREEMENT (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 18, 2019
Sep. 30, 2021
Sep. 30, 2020
Offsetting Assets [Line Items]          
Revenue recognized from assets sale $ 0 $ 9,888   $ 75,000 $ 30,761
Asset Purchase Agreement [Member] | Ani Pharmaceuticals [Member]          
Offsetting Assets [Line Items]          
Revenue recognized from assets sale     $ 2,300,000    
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details)
Sep. 30, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2021 (remaining 3 months) $ 11,250
2022 $ 18,750
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]    
Operating lease expense $ 33,750 $ 32,250
Royalty payable 1,000,000  
Proceeds from royalties $ 0 $ 250,000
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
401(k) PROFIT-SHARING PLAN (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Retirement Benefits [Abstract]    
Employer contribution $ 0 $ 0
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]        
Income tax expense benefit $ 0 $ 0 $ 0 $ 0
EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 143 240 1 false 35 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://coeptistx.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://coeptistx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Sheet http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - LICENSE RIGHT Sheet http://coeptistx.com/role/LicenseRight LICENSE RIGHT Notes 9 false false R10.htm 00000010 - Disclosure - LONG-TERM DEBT Sheet http://coeptistx.com/role/Long-termDebt LONG-TERM DEBT Notes 10 false false R11.htm 00000011 - Disclosure - CAPITAL STRUCTURE Sheet http://coeptistx.com/role/CapitalStructure CAPITAL STRUCTURE Notes 11 false false R12.htm 00000012 - Disclosure - ASSET PURCHASE AGREEMENT Sheet http://coeptistx.com/role/AssetPurchaseAgreement ASSET PURCHASE AGREEMENT Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://coeptistx.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - 401(k) PROFIT-SHARING PLAN Sheet http://coeptistx.com/role/KProfit-sharingPlan 401(k) PROFIT-SHARING PLAN Notes 14 false false R15.htm 00000015 - Disclosure - INCOME TAXES Sheet http://coeptistx.com/role/IncomeTaxes INCOME TAXES Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENT Sheet http://coeptistx.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - LONG-TERM DEBT (Tables) Sheet http://coeptistx.com/role/Long-termDebtTables LONG-TERM DEBT (Tables) Tables http://coeptistx.com/role/Long-termDebt 18 false false R19.htm 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://coeptistx.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://coeptistx.com/role/CommitmentsAndContingencies 19 false false R20.htm 00000020 - Disclosure - LICENSE RIGHT (Details Narrative) Sheet http://coeptistx.com/role/LicenseRightDetailsNarrative LICENSE RIGHT (Details Narrative) Details http://coeptistx.com/role/LicenseRight 20 false false R21.htm 00000021 - Disclosure - LONG-TERM DEBT (Details) Sheet http://coeptistx.com/role/Long-termDebtDetails LONG-TERM DEBT (Details) Details http://coeptistx.com/role/Long-termDebtTables 21 false false R22.htm 00000022 - Disclosure - LONG-TERM DEBT (Details Narrative) Sheet http://coeptistx.com/role/Long-termDebtDetailsNarrative LONG-TERM DEBT (Details Narrative) Details http://coeptistx.com/role/Long-termDebtTables 22 false false R23.htm 00000023 - Disclosure - CAPITAL STRUCTURE (Details Narrative) Sheet http://coeptistx.com/role/CapitalStructureDetailsNarrative CAPITAL STRUCTURE (Details Narrative) Details http://coeptistx.com/role/CapitalStructure 23 false false R24.htm 00000024 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative) Sheet http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative ASSET PURCHASE AGREEMENT (Details Narrative) Details http://coeptistx.com/role/AssetPurchaseAgreement 24 false false R25.htm 00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://coeptistx.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://coeptistx.com/role/CommitmentsAndContingenciesTables 25 false false R26.htm 00000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://coeptistx.com/role/CommitmentsAndContingenciesTables 26 false false R27.htm 00000027 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative) Sheet http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative 401(k) PROFIT-SHARING PLAN (Details Narrative) Details http://coeptistx.com/role/KProfit-sharingPlan 27 false false R28.htm 00000028 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://coeptistx.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://coeptistx.com/role/IncomeTaxes 28 false false All Reports Book All Reports coeptis_i10q-093021.htm coep-20210930.xsd coep-20210930_cal.xml coep-20210930_def.xml coep-20210930_lab.xml coep-20210930_pre.xml coeptis_ex3101.htm coeptis_ex3102.htm coeptis_ex3201.htm coeptis_ex3202.htm http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 45 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "coeptis_i10q-093021.htm": { "axisCustom": 0, "axisStandard": 9, "contextCount": 143, "dts": { "calculationLink": { "local": [ "coep-20210930_cal.xml" ] }, "definitionLink": { "local": [ "coep-20210930_def.xml" ] }, "inline": { "local": [ "coeptis_i10q-093021.htm" ] }, "labelLink": { "local": [ "coep-20210930_lab.xml" ] }, "presentationLink": { "local": [ "coep-20210930_pre.xml" ] }, "schema": { "local": [ "coep-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 297, "entityCount": 1, "hidden": { "http://coeptistx.com/20210930": 11, "http://fasb.org/us-gaap/2021-01-31": 84, "http://xbrl.sec.gov/dei/2021": 5, "total": 100 }, "keyCustom": 14, "keyStandard": 226, "memberCustom": 29, "memberStandard": 5, "nsprefix": "coep", "nsuri": "http://coeptistx.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://coeptistx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - LONG-TERM DEBT", "role": "http://coeptistx.com/role/Long-termDebt", "shortName": "LONG-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - CAPITAL STRUCTURE", "role": "http://coeptistx.com/role/CapitalStructure", "shortName": "CAPITAL STRUCTURE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "coep:AssetPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - ASSET PURCHASE AGREEMENT", "role": "http://coeptistx.com/role/AssetPurchaseAgreement", "shortName": "ASSET PURCHASE AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "coep:AssetPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://coeptistx.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - 401(k) PROFIT-SHARING PLAN", "role": "http://coeptistx.com/role/KProfit-sharingPlan", "shortName": "401(k) PROFIT-SHARING PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - INCOME TAXES", "role": "http://coeptistx.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENT", "role": "http://coeptistx.com/role/SubsequentEvent", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - LONG-TERM DEBT (Tables)", "role": "http://coeptistx.com/role/Long-termDebtTables", "shortName": "LONG-TERM DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://coeptistx.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedContractualRightsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - LICENSE RIGHT (Details Narrative)", "role": "http://coeptistx.com/role/LicenseRightDetailsNarrative", "shortName": "LICENSE RIGHT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - LONG-TERM DEBT (Details)", "role": "http://coeptistx.com/role/Long-termDebtDetails", "shortName": "LONG-TERM DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - LONG-TERM DEBT (Details Narrative)", "role": "http://coeptistx.com/role/Long-termDebtDetailsNarrative", "shortName": "LONG-TERM DEBT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - CAPITAL STRUCTURE (Details Narrative)", "role": "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "shortName": "CAPITAL STRUCTURE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)", "role": "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative", "shortName": "ASSET PURCHASE AGREEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "coep:AssetPurchaseAgreementTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2019-01-012019-06-18_custom_AssetPurchaseAgreementMember_custom_AniPharmaceuticalsMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://coeptistx.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - 401(k) PROFIT-SHARING PLAN (Details Narrative)", "role": "http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative", "shortName": "401(k) PROFIT-SHARING PLAN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://coeptistx.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "role": "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2020-01-012020-03-31_custom_PreferredStockSeriesBMember", "decimals": "0", "lang": null, "name": "coep:RetroactiveApplicationOfRecapitalization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "role": "http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation", "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - LICENSE RIGHT", "role": "http://coeptistx.com/role/LicenseRight", "shortName": "LICENSE RIGHT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "coeptis_i10q-093021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "coep_AccountingNonEmployeeShareBasedPaymentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting for non-employee share-based payments" } } }, "localname": "AccountingNonEmployeeShareBasedPaymentsPolicyTextBlock", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "coep_AdjustedBalanceBeginningOfPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Adjusted balance, beginning of period" } } }, "localname": "AdjustedBalanceBeginningOfPeriod", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "coep_AdjustedBalanceBeginningOfPeriodShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjusted balance, beginning of period, Shares" } } }, "localname": "AdjustedBalanceBeginningOfPeriodShares", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "coep_AniPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ani Pharmaceuticals [Member]" } } }, "localname": "AniPharmaceuticalsMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_AssetPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Purchase Agreement [Member]" } } }, "localname": "AssetPurchaseAgreementMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_AssetPurchaseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSET PURCHASE AGREEMENT" } } }, "localname": "AssetPurchaseAgreementTextBlock", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreement" ], "xbrltype": "textBlockItemType" }, "coep_CapitalDistributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Capital distributions" } } }, "localname": "CapitalDistributions", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "coep_CommonStockSubscribed": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock subscribed" } } }, "localname": "CommonStockSubscribed", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "coep_CommonStockSubscribedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Subscribed [Member]" } } }, "localname": "CommonStockSubscribedMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "coep_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_ConsensiLicenseRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consensi License Right [Member]" } } }, "localname": "ConsensiLicenseRightMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_ConsultingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Services [Member]" } } }, "localname": "ConsultingServicesMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "coep_CoralInvestmentPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Coral Investment Partners [Member]" } } }, "localname": "CoralInvestmentPartnersMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_DisclosureAssetPurchaseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Purchase Agreement" } } }, "localname": "DisclosureAssetPurchaseAgreementAbstract", "nsuri": "http://coeptistx.com/20210930", "xbrltype": "stringItemType" }, "coep_EidlLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EIDL Loan [Member]" } } }, "localname": "EidlLoanMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayable1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 1 [Member]" } } }, "localname": "NotePayable1Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayable2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 2 [Member]" } } }, "localname": "NotePayable2Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayable3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 3 [Member]" } } }, "localname": "NotePayable3Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayable4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 4 [Member]" } } }, "localname": "NotePayable4Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayable5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 5 [Member]" } } }, "localname": "NotePayable5Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayable6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 6 [Member]" } } }, "localname": "NotePayable6Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayable7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 7 [Member]" } } }, "localname": "NotePayable7Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_NotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable [Member]" } } }, "localname": "NotePayableMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_OtherSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Sales [Member]" } } }, "localname": "OtherSalesMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "coep_PppLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PPP Loan [Member]" } } }, "localname": "PppLoanMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_PreferredStockSeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Series B [Member]" } } }, "localname": "PreferredStockSeriesBMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "coep_PurpleBioTechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purple Bio Tech [Member]" } } }, "localname": "PurpleBioTechMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_RetroactiveApplicationOfRecapitalization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Retroactive application of recapitalization" } } }, "localname": "RetroactiveApplicationOfRecapitalization", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "coep_RetroactiveApplicationOfRecapitalizationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retroactive application of recapitalization, shares", "label": "Retroactive application of recapitalization, shares" } } }, "localname": "RetroactiveApplicationOfRecapitalizationShares", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "coep_RoyaltiesAndLicensingIncomeFees": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Royalties and licensing fees" } } }, "localname": "RoyaltiesAndLicensingIncomeFees", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "coep_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_SharesFromMergerTransaction": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesFromMergerTransaction", "negatedLabel": "Shares from merger transaction" } } }, "localname": "SharesFromMergerTransaction", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "coep_SharesIssuedForConversionOfDebt": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "SharesIssuedForConversionOfDebt", "negatedLabel": "Shares issued for conversion of debt" } } }, "localname": "SharesIssuedForConversionOfDebt", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "coep_SharesIssuedThroughConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued through conversion of debt" } } }, "localname": "SharesIssuedThroughConversionOfDebt", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "coep_SharesIssuedThroughConversionOfDebtShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued through conversion of debt, Shares" } } }, "localname": "SharesIssuedThroughConversionOfDebtShares", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "coep_VyGenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "VyGen-Bio [Member]" } } }, "localname": "VyGenMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_VyGenOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vy Gen Options [Member]" } } }, "localname": "VyGenOptionsMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_WarrantClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Class A [Member]" } } }, "localname": "WarrantClassAMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_WarrantClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Class B [Member]" } } }, "localname": "WarrantClassBMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_WarrantHolder1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Holder 1 [Member]" } } }, "localname": "WarrantHolder1Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_WarrantHolder2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Holder 2 [Member]" } } }, "localname": "WarrantHolder2Member", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_WarrantHolderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Holder [Member]" } } }, "localname": "WarrantHolderMember", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "coep_WarrantsIssuedForServices": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[custom:WarrantsIssuedForServices]", "verboseLabel": "Warrants issued for services" } } }, "localname": "WarrantsIssuedForServices", "nsuri": "http://coeptistx.com/20210930", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r374", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://coeptistx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r44", "r46", "r85", "r86", "r180", "r209" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative", "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r136", "r233", "r235", "r314", "r354", "r355" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r136", "r233", "r235", "r314", "r354", "r355" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r45", "r46", "r85", "r86", "r180", "r209" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative", "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r18", "r139", "r140" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r334", "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Royalty payable" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r26", "r154" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r251", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r89", "r90", "r91", "r248", "r249", "r250", "r279" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Additional paid in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r246", "r247", "r252", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r175", "r222", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Warrants issued for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r70", "r144", "r149" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r81", "r125", "r128", "r134", "r142", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r270", "r275", "r282", "r307", "r309", "r331", "r343" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r41", "r81", "r142", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r270", "r275", "r282", "r307", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r88", "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/DescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r24", "r309", "r361", "r362" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "CASH AT END OF PERIOD", "periodStartLabel": "CASH AT BEGINNING OF PERIOD" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r65", "r283" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r78", "r81", "r101", "r102", "r103", "r105", "r107", "r109", "r110", "r111", "r142", "r164", "r168", "r169", "r170", "r173", "r174", "r206", "r207", "r211", "r215", "r282", "r380" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r160", "r335", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES (NOTE 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r157", "r158", "r159", "r161", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r89", "r90", "r279" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r222" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value, 750,000,000 shares authorized, 34,750,733 and 25,178,840 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": { "auth_ref": [ "r236", "r237", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "401(k) PROFIT-SHARING PLAN" } } }, "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/KProfit-sharingPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r77", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r231", "r232", "r234" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r57", "r81", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r282" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of goods, including inventory obsolescence" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r178", "r195" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r176", "r196", "r197", "r292", "r294", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r33", "r189", "r292" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt interest rate increase if in default" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r33", "r177" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r34", "r179", "r281" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "verboseLabel": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative", "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r35", "r80", "r87", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r196", "r197", "r198", "r199", "r223", "r226", "r227", "r228", "r291", "r292", "r294", "r295", "r341" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r238", "r239", "r240", "r242", "r243", "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Employer contribution" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/KProfit-sharingPlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r70", "r123" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOSS PER SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Loss per share, basic and fully diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r89", "r90", "r91", "r93", "r98", "r100", "r108", "r143", "r222", "r229", "r248", "r249", "r250", "r259", "r260", "r279", "r284", "r285", "r286", "r287", "r288", "r289", "r356", "r357", "r358", "r385" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedContractualRightsGross": { "auth_ref": [ "r148" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of an intangible asset that arises from a contractual arrangement with a third party (not including franchise rights and license agreements).", "label": "Co-development options", "verboseLabel": "License right" } } }, "localname": "FiniteLivedContractualRightsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets", "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r145", "r146", "r148", "r150", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r145", "r147" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r70", "r152", "r156" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on write down of assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r70", "r200", "r201" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Forgiveness of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r56", "r81", "r125", "r127", "r130", "r133", "r135", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r282" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r54", "r125", "r127", "r130", "r133", "r135", "r329", "r336", "r339", "r351" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r82", "r256", "r257", "r258", "r261", "r263", "r265", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r99", "r100", "r124", "r255", "r262", "r264", "r352" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "PROVISION FOR INCOME TAXES (BENEFIT)", "verboseLabel": "Income tax expense benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations", "http://coeptistx.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes paid (refunded)" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r69" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r69" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r69" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r69", "r312" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r69" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (decrease) in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r69", "r302" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Right of use asset/liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "LICENSE RIGHT" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRight" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r52", "r122", "r290", "r293", "r338" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r334", "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r39", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r70" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Shares issued for non-employee services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r81", "r129", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r271", "r275", "r276", "r282", "r307", "r308" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LONG TERM LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r81", "r142", "r282", "r309", "r333", "r346" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32", "r81", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r271", "r275", "r276", "r282", "r307", "r308", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r7", "r8", "r9", "r13", "r14", "r81", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r271", "r275", "r276", "r282", "r307", "r308" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "TOTAL LONG TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r184", "r194", "r196", "r197", "r332", "r344" ], "calculation": { "http://coeptistx.com/role/Long-termDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r87", "r162", "r188" ], "calculation": { "http://coeptistx.com/role/Long-termDebtDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r87", "r162", "r188" ], "calculation": { "http://coeptistx.com/role/Long-termDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r87", "r162", "r188" ], "calculation": { "http://coeptistx.com/role/Long-termDebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r87", "r162", "r188" ], "calculation": { "http://coeptistx.com/role/Long-termDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r87", "r162", "r188" ], "calculation": { "http://coeptistx.com/role/Long-termDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Note payable" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r35", "r163" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r68", "r71" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r47", "r48", "r51", "r55", "r71", "r81", "r92", "r94", "r95", "r96", "r97", "r99", "r100", "r104", "r125", "r127", "r130", "r133", "r135", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r280", "r282", "r337", "r350" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "NET LOSS", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Adoption of New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "TOTAL OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r13", "r332", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "verboseLabel": "Note payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable, current portion" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r27", "r84", "r305" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable, related parties, current portion" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COST OF OPERATIONS" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r125", "r127", "r130", "r133", "r135" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r300" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Right of use liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r300" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Right of use liability, non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r299" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset, net of accumulated amortization" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r296", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "verboseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2021 (remaining 3 months)" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r12", "r330", "r342" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "totalLabel": "Total other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r40", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r353" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r70" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Interest paid" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r60" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchase of license right" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r206" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r206" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series B Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, 8,000 and -0- shares issued and outstanding, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Issuance of convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r61" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Shares issued for cash" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from loan" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r62" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherEquity": { "auth_ref": [ "r61" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the issuance of equity classified as other.", "label": "Cash received for stock subscription" } } }, "localname": "ProceedsFromOtherEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r62" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from notes payable, related parties" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Repayment of notes payable, related parties" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRoyaltiesReceived": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for royalties during the current period.", "label": "Proceeds from royalties" } } }, "localname": "ProceedsFromRoyaltiesReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r47", "r48", "r51", "r64", "r81", "r92", "r99", "r100", "r125", "r127", "r130", "r133", "r135", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r269", "r273", "r274", "r277", "r278", "r280", "r282", "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r25", "r153" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Furniture and fixtures" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r155", "r309", "r340", "r347" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Furniture and fixtures, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r241", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r241", "r303", "r306", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r63" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r254", "r313", "r364" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r229", "r251", "r309", "r345", "r359", "r360" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r89", "r90", "r91", "r93", "r98", "r100", "r143", "r248", "r249", "r250", "r259", "r260", "r279", "r356", "r358" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r53", "r81", "r120", "r121", "r126", "r131", "r132", "r136", "r137", "r138", "r142", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r282", "r339" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Total sales", "verboseLabel": "Revenue recognized from assets sale" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SALES" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r145", "r147", "r315" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/LicenseRightDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of future minimum rental payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "verboseLabel": "LONG-TERM DEBT" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r37", "r78", "r109", "r110", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r215", "r220", "r223", "r224", "r225", "r226", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r69" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at ending, shares", "periodStartLabel": "Balance at beginning, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r76", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r78", "r81", "r101", "r102", "r103", "r105", "r107", "r109", "r110", "r111", "r142", "r164", "r168", "r169", "r170", "r173", "r174", "r206", "r207", "r211", "r215", "r222", "r282", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r38", "r49", "r50", "r51", "r89", "r90", "r91", "r93", "r98", "r100", "r108", "r143", "r222", "r229", "r248", "r249", "r250", "r259", "r260", "r279", "r284", "r285", "r286", "r287", "r288", "r289", "r356", "r357", "r358", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r89", "r90", "r91", "r108", "r314" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r222", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued for cash, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Number of share issued" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r222", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Shares issued for cash" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r81", "r141", "r142", "r282", "r309" ], "calculation": { "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets", "http://coeptistx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r79", "r207", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "CAPITAL STRUCTURE" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructure" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/AssetPurchaseAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/Long-termDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r112", "r113", "r114", "r115", "r116", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrant expiration date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CapitalStructureDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://coeptistx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r365": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r366": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r367": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r368": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r369": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r371": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r372": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r373": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r374": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r375": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r376": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r377": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r378": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r379": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r381": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r382": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r383": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r384": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" } }, "version": "2.1" } ZIP 46 0001683168-21-005683-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-21-005683-xbrl.zip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end